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To all organ transplanted patients 
 

  
ABSTRACT 
Organ transplant recipients (OTRs) have an increased risk of developing a broad spectrum of 
cancer types, mainly skin cancer. Posttransplantation risk and incidence vary among the three 
major skin cancer types: cutaneous squamous cell carcinoma (SCC), basal cell carcinoma 
(BCC), and cutaneous malignant melanoma (melanoma). The etiology is multifactorial but 
long-term immunosuppression, leading to impaired tumor surveillance and viral defense, is 
probably the main factor. The overall aim of this thesis is to improve the understanding of the 
greatly increased risk of skin cancer in this patient group. The investigations were portioned 
into four parts. 
Study 1 aimed at gaining a better insight into the link between SCC and the surrounding 
inflammatory infiltrate. The percentage distributions and cell densities (cells/mm2 tumor 
section area) in the peritumoral infiltrate of SCCs were therefore compared between OTRs 
and immunocompetent control patients. In conclusion, the peritumoral infiltrates in OTRs 
differed in cellular composition, although not in cell densities, which was surprising and 
implying a more tumor-submissive microenvironment.  
To further address the aim, data from population-based and nation-wide healthcare registers, 
mandatory cancer reporting and the Swedish Melanoma Register were evaluated: 
In Study 2, the risk of posttransplantation cancer was analyzed overall, by anatomical site 
and by transplanted organ. The Swedish cohort of OTRs, transplanted 1970 – 2008 and 
including more than 10,000 patients were compared with the general population (SIR = 
standardized incidence ratio). The relative risk of cancer varied by anatomical site, with the 
bulk of the excess risk being coupled with an exceptionally high risk of SCC (120-fold). The 
risk estimates were highest in heart and/or lung (198-fold) and lowest in liver OTRs (32-
fold). During follow-up the risk of SCC tripled over 20 years irrespective of graft type, 
whereas risk of cancer overall, excluding SCC, remained stable. These findings underscore 
the importance of regular skin screening in OTRs.  
In Study 3 clinicopathological characteristics of 49 posttransplantation melanomas and 
mortality in comparison with melanomas from the general population were assessed. 
Melanomas in OTRs were more advanced at diagnosis with respect to Clark level and clinical 
stage, but not with respect to millimeter thickness. The risk of melanoma-specific death was 
3-fold increased in OTRs compared to the population. Histological reassessment revealed that 
73% of all melanomas in OTRs (36 out of 49 cases) were associated with a melanocytic 
nevus, mainly of the dysplastic/atypical type and the trunk was the most common nevus-
associated site (21/ 25, 84%). This fact may be a reason to consider prophylactic excision of 
truncal nevi among OTRs. Also, only very few cases demonstrated abundant tumor-
infiltrating lymphocytes (TILs), indicating that more variables than just millimeter thickness 
may be associated with prognosis of posttransplantation melanoma. 
In Study 4 the relative risk of BCC in 4,023 OTRs, transplanted 2004 – 2011, were compared 
with the general population (SIR = standardized incidence ratio) by using the 2004 
established Basal Cell Carcinoma Register. The risk of BCC among OTRs was 6-fold 
increased and the risk was highest in kidney (7.2-fold) and lowest in liver OTRs (2.6-fold). 
The risk of BCC increased with time since transplantation and was also increased in patients 
≥65 years at transplantation. In comparison to BCC, the SCC incidence was lower and 
resulted in a SCC to BCC ratio of 1: 1.7, which was considerably less than previously 
reported and may have depended on length of follow-up time.	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1 BACKGROUND 
1.1 INTRODUCTION 
The transplantation of a solid organ means the opportunity for a new life as it opens a chance 
of becoming free from the physical and psychological restraints of a failing organ. The 
transplantation of a new healthy organ is a gift of life as it puts back in balance what had been 
acutely or chronically lost.1  
The modern history of organ transplantation started with treatment of burned aviators in 
World War II in Britain by investigating the use of skin grafts. The fate of the patient’s own 
skin (autograft) was compared to that of another person’s (allograft) and the phenomenon of 
rejection was identified.2 The concept of self- and non-self recognition paved the way for the 
definition of transplantation tolerance. The first method of immunosuppression was by total 
body irradiation, described as “blunt and unpredictable”.2 Controlling rejection advanced 
with the use of corticosteroids, often in combination with azathioprine, which was discovered 
in 1959. The breakthrough did not come until cyclosporine, one of the most powerful 
immunosuppressants, was discovered in the beginning of the 1970s and came into clinical use 
from the early 1980s. The use of cyclosporine doubled the 5-year survival and led to a 
dramatic increase in solid organ transplantations, only constrained by donor availability.1  
The first successful kidney transplantation was performed in 1954 in Boston in monozygotic 
twins, thus no immunosuppression was needed. The first lung and liver transplantations were 
performed in 1963 in the USA, as well as the first pancreas in 1966. The first heart 
transplantation took place in South Africa in 1967. The results of these early solid organ 
transplantations were often disappointing but with improvements in controlling rejection as 
well as surgical methods survival after transplantation improved steadily from the late 1970s. 
Several achievements in transplantation medicine have been honored with the Nobel Prize.3  
In Sweden the first kidney was transplanted in 1964 at the Serafimer Lasarettet in Stockholm. 
Since then, altogether more than 19,000 organs have been transplanted in Sweden (1964 – 
2014), with the vast majority being kidneys, >70%, Figure 1. 
Under the premises of life-long immunosuppression, long-term quality of life4 and survival 
rates5 after organ transplantation are nowadays usually good. A drawback though, is the 
substantial risk of developing malignancies, with 90% of all malignancies in fair-skinned 
organ transplant recipients (OTRs) being keratinocyte skin cancers (KCs)6, namely cutaneous 
squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs), while cutaneous 
malignant melanoma (melanoma) incidence is only moderately increased.6 The life-
threatening potential of some skin cancer types has been demonstrated in an Australian study7 
of heart OTRs. Here 27% of deaths occurring after the 4th year posttransplantation were due 
to skin cancers (SCCs, melanomas and Merkel cell carcinoma). Also, more rare skin cancer 
types, for example Kaposi’s sarcoma (KS) and Merkel cell carcinoma (MCC) are increased 
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in OTRs6, which, at least in KS, also depends on the genetic background and the occurrence 
of the causative virus in different populations.8, 9  
 
  
Figure 1 illustrates the frequency of transplantation by organ type, from 1964 – 2014. 
 
The risk is also elevated for a number of other cancer types and one of the first population-
based studies from the Nordic countries10, showed a 4.6-fold overall excess risk of cancer in 
kidney OTRs. However, the most prevalent cancer types in the general population, e.g. breast 
and prostate cancer, seem not or only marginally increased in OTRs.10-17 With the rising 
proportion of pediatric OTRs, the risk of early posttransplantation lymphoproliferative 
disorders has also become more obvious12, 18, 19, and already in 1969, lymphomas were the 
first malignancy to be related to immunosuppression by Penn et al.20  
The etiology of posttransplantation malignancies in the skin is multifactorial but there is 
strong evidence that the state of immunodeficiency caused by the immunosuppressive drugs 
is an essential, perhaps the main, contributing factor.6, 21-27 Some drugs have shown to 
become carcinogenic in conjunction with ultraviolet radiation23, 24, 26, which is currently 
believed to be one of the main reasons for the marked increased incidence especially for 
SCCs. Other authors have shown that the duration of immunosuppressive therapy rather than 
any specific type or combination of drugs is crucial.28-32  
Figure 1. Transplantation in Sweden 1964 – 2014 
(according to data from svensktransplantationsforening.se and socialstyrelsen.se) 
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For a number of non-skin and skin malignancies, the marked susceptibility to infections in 
OTRs leads to increased incidence of tumors associated with oncogenic viruses, for example 
posttransplantation lymphoproliferative disorders (Epstein-Barr Virus and also Hepatitis 
C)18, 33, hepatocellular carcinoma (mainly Hepatitis C and B)34, cervical cancer and cancer 
of the outer genital tract (human papilloma virus, HPV), KS (human herpes virus 8, 
HHV8)35, 36, and MCC (Merkel cell polyoma virus, MCPyV).37 The underlying disease can 
in some patients also lead to an increased risk of a malignancy16, 38, 39, for example in patients 
with diabetes mellitus or end-stage kidney disease. Finally, the likelihood to develop a 
malignancy is also dependent on the individual genetic susceptibility and on age. 
OTRs can be regarded as a model population, suitable for studying mechanisms of skin 
carcinogenesis. However, OTRs have, compared to the general population, specific 
prerequisites that must be accounted for and balanced out against the general conditions, such 
as sun damage, to permit generalization of OTR data. To deduce specific risk factors for skin 
cancer in OTRs is therefore one of the aims of this thesis.  
The overall aim is to investigate the dramatic increase of skin cancer incidence, i.e. SCC, 
BCC, and melanoma, in Swedish OTRs and to improve the understanding of the greatly 
increased risks by focusing on histopathological and epidemiological aspects, with the 
ultimate goal to improve patient care.  
Key findings of this thesis are: 
The peritumoral infiltrate in SCC differs in cellular composition, but not in cellular densities 
from control tumors, indicating a possible tumor-promoting microenvironment in OTRs  
The relative risk of SCC overrides all other cancer risk posttransplantation. It differs by organ 
type and increases with time after transplantation 
The relative risk of BCC is increased in a cohort of recently transplanted patients with the 
lowest risk in liver OTRs 
Assessment of clinico-pathological characteristics of posttransplant melanomas indicate that 
variables such as Clark level, nevus association and tumor-infiltrating lymphocytes, besides 
millimeter thickness, may have impact on melanoma mortality 
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1.2 SKIN CANCER 
The fair-skinned population of the industrialized, so called Western, world is in the midst of a 
skin cancer epidemic40, the end of which is not to be expected during the near future. 
Incidence rates of skin cancer correlate not only with latitude, but also with excessive sun 
seeking behavior in populations of more temperate climate zones. Another factor is increased 
longevity.  
In 2013 incidences of the three skin cancer types in Sweden41 were 45,590 basal cell 
carcinomas (BCCs), followed by 6,384 cutaneous squamous cell carcinomas (SCCs) and 
3,358 cutaneous malignant melanomas (melanomas). The skin cancer group, excluding BCC, 
accounted for 16% of all malignancies. 
Comparison of skin cancer incidences with other Nordic countries is easiest by using the 
NORDCAN database (2008 – 2012)42, 43 and the recent publication from GLOBOCAN 
(world data from 2012).44 The age-standardized incidence rates (ASRs), adjusted to world 
standard, for skin cancers in Sweden and Denmark as well as Australia/New Zealand are 
shown in Table 1. 
 
Table 1. Skin cancer incidence and mortality in Sweden and Denmark in 
comparison to Australia and New Zealand 
  SCC BCC Melanoma 
  Males Females Males Females Males Females 
Sweden ASR 17.2a 11.4a NA NA 17.2a 18.1a 
 Mortality 0.3 0.1 NA NA 3.1 1.9 
Denmark ASR 18.2a 10.9a 91b 97b 20.5a 25.5a 
 Mortality 0.5 0.3 NA NA 3.1 1.8 
Australia/
New 
Zealand 
ASR 499c 291c 1,041c 745c 40d 31d 
 Mortality NA NA NA NA 6.0 2.4 
aASR denotes age-standardized rate (number of cases per 100,000) according to NORDCAN42, 43; 
bASR reported by Birch-Johansen et al.45; 
cASR reported by Staples et al.46; dASR according to GLOBOCAN44 
Mortality denotes number of deaths per 100,000 age-standardized and adjusted to world standard 
NA denotes not applicable: Because BCCs are not included in NORDCAN and GLOBOCAN databases, because 
mortality of BCC is not included in Birch-Johansen et al.44, and mortality data on non-melanoma skin cancer is not 
included in Staples et al.45 
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In Denmark, cancers are listed in two registers, in the Danish Cancer Register, which records 
only the first incident histological type of skin cancer, and in the Danish Register of 
Pathology, which records all cancers. Therefore underestimation of true skin cancer incidence 
due to incomplete registration has been recognized in Denmark.45  
In Australia, population-based register data on skin cancer, except melanoma, is lacking. 
Australia and New Zealand have the highest incidence of skin cancer in the world.46, 47 To 
estimate trends of skin cancer incidence in Australia, interview surveys with skin cancer 
patients were held and analyzed for the years 1985 – 2002 (every 5 years).46 Age-specific 
incident rates were highest in both genders ≥70 years. In a recent study by Whiteman et al.48 
of skin cancer, incident rates were indirectly estimated by analyzing population-wide medical 
service registers on surgical treatment of skin cancer, i.e. SCC, BCC, and melanoma. The 
authors reported significantly decreased treatment rates in patients <45 years, while 
treatment rates for all three skin cancer types had still risen in Australians ≥55 years. The 
decrease of treatment rates in the younger age group was interpreted as a benefit of 
prevention campaigns initiated in the 1980s.48  
Organ transplantation has brought a new dimension to the skin cancer epidemic. In OTRs the 
incidence of skin cancer accounts for 24% – 69% of all malignancies posttransplantation.11, 12, 
14, 15, 49 Variations depend largely on the mode of cancer registration, i.e. reporting of only the 
first of multiple tumors in any one individual leads to underestimation of true incidence.  
The medical community is well aware of the immense problem of posttransplantation skin 
cancer. The number of hits when searching the PUBMED.gov database illustrates this. More 
than 1,000 articles have been published for the search combination “skin cancer and organ 
transplant recipients”, and double this number was found for “skin cancer and organ 
transplantation”. When filtering for “cancer and organ transplantation and population-based” 
less than 100 papers could be retrieved, showing the relative scarcity of population-based 
epidemiological studies in this field. The latter is probably due to incomplete cancer 
registration in many countries. The longstanding Swedish tradition of highly reliable, 
nationwide and mandatory health care registration, especially cancer registration, is therefore 
invaluable for studying cancer incidence in patient cohorts with different attributes, in order 
to broaden knowledge on etiological associations. 
 
1.2.1 Cutaneous squamous cell carcinoma (SCC) 
SCCs are malignant tumors of epidermal keratinocytes, i.e. belong to the group of 
keratinocyte cancers (KCs). The epidermis is the stratified and keratinized surface epithelium 
covering 99% of the body surface, thus forming its largest organ. 
 
 14 
1.2.1.1 SCC incidence in general and in OTRs 
In Sweden, skin cancers, if excluding melanoma and BCC, consists mainly of SCCs 
(approximately 98%).50 For several years now, this group is ranked second most common 
cancer in males and in females, after prostate and breast cancer, respectively. During the past 
decade, the annual increase has been 4.9% in males and 6.5% in females.41 Increase in age-
specific incidence has been most dramatic in both genders ≥85 years, while incidence rates 
have not changed in males <60 years contrasting to a slight increase in females of the same 
age group.41  
The first report heralding an elevated incidence of multiple squamous malignancies in kidney 
OTRs came 1971 from Australia.51 In Sweden, Blohmé et al.52, 53 were the first to describe 
the broad spectrum of skin lesions in kidney OTRs. They found that the estimated risk of any 
skin malignancy was increased approximately 7-fold compared to a non-transplanted patient 
group, although the estimate was not population-based. Since then, SCC has been 
documented as by far the most frequent type of skin cancer in fair-skinned OTRs, and 
population-based estimates report of 65- to 250-fold increased risk.6, 14, 54-57 Highest rates 
have been reported in heart OTRs, which is mainly attributed to a higher level of 
immunosuppression and to older age at transplantation.6, 12, 57-60 According to population-
based data, risk of SCC is much lower in liver recipients12, 14, 56, which, along the same line, is 
associated with an often lower level of immunosuppression in liver OTRs.  
Cumulative incidence of SCC, alone or together with BCC, at 5 and 20 years 
posttransplantation, vary in different populations. There is a marked difference between 
northern and southern latitudes. For example in northern Europe cumulative incidence was 1–
3% at 5 years and 20% at 20 years posttransplantation in Sweden11, 14, 3% and 40% in the 
Netherlands29, 8% and 61%28 and 10% and 54%61 in the UK, compared with southern 
latitudes of New Zealand 12% and 54%62, and Queensland, Australia 25% and 70%29 and 
30% and 73%.63  
Age at transplantation is also a known factor for posttransplantation SCC development as 
demonstrated in a study from the UK.64 In OTRs with age at transplantation between 18 – 40 
years the mean interval for first SCC development was 13 years, while the mean time span 
was only 3 years in OTRs >60 years.  
1.2.1.2 SCC anatomical location in general and in OTRs 
SCCs mainly develop on chronically sun-exposed skin being characterized by actinic 
elastosis, mottled pigmentation, telangiectasia and multiple actinic keratoses (AKs). In a 
Swedish study65 on trends of SCC incidence according to age and body site distribution, most 
SCCs in both genders >50 years were head-neck tumors, i.e. in the most typical chronically 
sun-exposed site. In patients <50 years most SCCs were located on the trunk and the limbs. 
For nearly half a century, an increase of SCC incidence was observed for the trunk and upper 
limbs and this was interpreted as an effect of intermittent, intentional tanning.65  
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Compared with the general population, the anatomical distribution pattern of SCCs is similar 
in OTRs.66 The head-neck region is the most commonly affected in older male OTRs (born 
before 1940) while in females and in younger OTRs (born after 1940) the most common sites 
are the chest and the upper extremities, these being exposed to the sun intermittently. In this 
study a few patients with many SCCs influenced proportions of site distributions because 
some of their tumors were clustered on the same anatomical site, which is an effect of “field 
cancerization”.1, 66-68 
1.2.1.3 SCC histology and behavior in general and in OTRs 
Histologically SCCs consist of atypical nests and sheets of keratinocytic proliferations 
infiltrating from the surface epithelium into the underlying stroma, i.e. the dermis.69 The 
degree of anaplasia, including remaining squamous differentiation, is variable and is used to 
grade the tumors into well, moderately and poorly differentiated. This is considered to be a 
rather subjective assessment.69 Sporadic keratoacanthomas (KAs) are another type of 
squamous tumors arising on sun-exposed skin. After a rapid growth phase of 4 – 8 weeks, 
they spontaneously regress over a period of several months. KAs share morphologic 
characteristics with well-differentiated SCCs and current data support the argument that KAs 
are genetically incomplete SCCs and that this entity should be considered a distinct stage, i.e. 
an intermediate “pre-malignant” stage, in SCC carcinogenesis.70, 71  
In OTRs, histological assessment of SCCs more often reveals perineural and/or lymphatic 
invasion72, deep growth in the dermis and into the subcutis73, 74, denoted by Clark level IV 
and V, while a majority of cases exhibit high differentiation grade.73 Two studies have 
reported a decreased number of inflammatory cells surrounding tumors.75, 76 Features of 
acantholysis and of a viral etiology, i.e. human papilloma virus (HPV), were more common 
in SCCs from OTRs compared to non-transplanted controls.74, 75 An increased rate of local 
recurrence and metastasis6, 7, 29, 73-75, 77, 78 and a 52-fold increased mortality in OTRs compared 
with the general population73 has been attributed to the more aggressive behavior of SCCs.  
For the large majority of patients with SCCs, prognosis is excellent, whereas for a minority 
with potentially lethal SCCs, a staging system according to high-risk factors has recently 
been proposed.79 Clinical and histologic risk factors associated with increased risk of 
recurrence, metastasis and mortality are: tumor size >2cm, location on lip, ear, scalp, tumor 
relapse, pattern of deep infiltration beyond the dermis, perineural, and/or peri-/intravascular 
growth as well as poor differentiation.79 Further clinicopathological high-risk features include 
variants such as invasive Bowen’s disease, adenosquamous carcinoma, de novo SCC, i.e. 
SCC without evidence of a precursor lesion such as actinic keratosis, SCC arising in the 
setting of a chronic dermatitis, such as discoid lupus erythematous, lichen planus, lichen 
sclerosus, and SCC development in chronic ulcers, radiation-induced SCC, as well as 
underlying immunosuppression.80, 81 Several cases of skin cancer, mainly SCCs, in burn scars 
have been reported, however, population-based data did not show an increased skin cancer 
risk.82, 83  
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1.2.2 Basal cell carcinoma (BCC)  
BCCs are locally invasive malignant tumors and like SCCs belong to the group of KCs. It is 
generally considered that BCCs have no known precursor state and originate from pluripotent 
immature epidermal or follicular stem cells, encompassing organoid, i.e. epithelial and 
stromal, features.84 BCCs are stroma-depended and therefore metastasize only very rarely; 
hence, mortality due to BCC is very low. However, due to the number of cases in the general 
population, BCCs cause considerable morbidity.41  
1.2.2.1 BCC incidence and anatomical location in general and in OTRs 
In Sweden, BCC incidence has only been registered since 2004 in the BCC Register.85 Age-
standardized incidence rates are equal for both genders, nearly 500/100,000, and highest age-
specific incidence rates are reported in patients ≥85 years, 3,700/100,000 in males and 
approximately 2,000/100,000 in females.41 In OTRs, BCCs are the second most common skin 
cancer type and almost 30 – 50% of OTRs with SCC also develop BCCs.6 Comparative 
estimates of population-based relative risk of BCC have been difficult to obtain because of 
lack of comprehensive BCC registration in many countries. The few available studies have 
reported a 6- to 16-fold increased risk of BCC in OTRs compared to the general population.49, 
54, 56  
In the Swedish population, the majority of all BCCs are located in the head-neck region 
(approximately 55%) and the trunk (approximately 30%).85 In a Danish study, a significantly 
greater increase of BCC incidence was reported in patients <40 years, which was attributed to 
late effects of the use of tanning beds.45 Increasing BCC incidence in younger individuals 
have previously also been reported from the UK86, USA87 and the Netherlands.88 In OTRs, 
anatomical site distributions were similar to the general population75, 89, while more 
uncommon sites, such as dorsum of the hands28, 89, axillae and genitalia have also been 
reported.89 
1.2.2.2 BCC classification and behavior in general and in OTRs  
The classification used in Sweden is based on an estimation of the putative biological 
aggressiveness of the tumor, which has been evaluated in relation to relapse frequency.90 It is 
called Sabbatsberg or Glas classification and is intended to help guide the clinician in 
choosing the appropriate curative method for the different BCC types. Instead of a descriptive 
classification of cytological and structural differing forms, the tumor silhouette, i.e. growth 
pattern, depth of invasion, tumor circumscription and demarcation of the tumor border in 
relation to the surrounding stroma, as well as size and shape of tumor vegetations are 
evaluated (Table 2). Tumors are classified into five different types: low/non aggressive types 
IA and IB, moderate aggressive type II, high aggressive type III and metatypical type, which 
is also called basosquamous or mixed type, exhibiting features of keratinization. In the first 
report from the Swedish BCC Register85, the most prevailing BCC types were the low and 
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moderately aggressive types, together >80%. Histological evaluations of BCCs in OTRs have 
not revealed more aggressive tumor characteristics.72, 75, 89  
To facilitate comparability with the WHO BCC classification, see Table 2. 
 
Table 2: Classification of Basal Cell Carcinoma types in Sweden90 
compared to WHO classification69 
BCC type 
 
ICD-O/3 
Classification according 
to putative 
aggressiveness 
Corresponding WHO 
classification 
Tumor silhouette 
Low 
aggressive 
IA 
M809031 
Well demarcated, coherent 
growth of solid, cystic, 
adenoid vegetations, often 
nodular or broadly budding. 
Pushing or even border 
Palisading and basaloid 
Includes fibroepithelioma of 
Pinkus 
Mainly nodular, can be 
cystic, adenoid, keratotic, 
pigmented, and can show 
adnexal differentiation. 
 
Low 
aggressive 
IB 
M80913 
Multiple small basaloid 
vegetations, continuous 
with the epidermis or hair 
follicle epithelium. 
Tumor growth is restricted 
to the papillary dermis or 
the perifollicular adventitial 
stroma. 
Superficial growth, can be 
adenoid, and pigmented. 
 
Moderate 
aggressive 
II 
M809032 
Infiltrative, micronodular, 
irregular small budding 
growth 
Irregular/uneven deep 
border, not pushing and not 
diffuse (versus III) 
Variable palisading 
Infiltrative, micronodular, 
adenoid, pigmented, can 
show adnexal 
differentiation or be of 
basosquamous type. 
 
High 
aggressive 
III 
M809033 
Diffusely infiltrative, 
demerging or growth into 
subcutis, intramuscular, 
cartilage or bone, often not 
palisading, can be of 
morphoeic type. 
+/- sclerosing stroma 
Morphoeic and sclerosing 
 
Drawings are reproduced with permission from Dr. Lennart Hedenborg, Stockholm 
 
1.2.3 Cutaneous malignant melanoma (melanoma) 
Melanomas arise from pigment producing cells, i.e. melanocytes, in epidermis, adnexal 
epithelia, or dermis. Melanoma is not a single tumor but rather a group of entities with 
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various histological, phenotypical and molecular characteristics.91 In melanoma in situ the 
proliferation and expansion of atypical melanocytes is limited to the epidermis and adnexal 
epithelium, whereas invasion into the underlying dermis denotes the invasive phase. 
Melanoma is a highly malignant tumor and responsible for greater mortality than any other 
skin cancer.  
 
1.2.3.1 Melanoma incidence in general and in OTRs 
In Sweden, melanoma is ranked 6th most common malignancy in males and 5th in females 
(melanoma in situ not included). The annual increase has been approximately 5% in both 
genders during the past 10 years.41 The age-specific incidence is in males highest >60 years 
and in females highest <50 years. Within Sweden, melanoma incidence has been reported 
higher in western coastal regions compared to inland regions92 and also higher in the south 
compared to the north.93 Lately, decreasing trends in melanoma incidence among adolescents 
and younger adults in Sweden94 and in other countries95-97 have been reported. These 
encouraging findings have been attributed to a growing awareness of the risk of sun exposure 
and to improved surveillance leading to early diagnosis.48, 94, 96, 97  
Risk of posttransplantation melanoma shows an approximately 2 – 3-fold increase compared 
to the general population98, with a higher risk in male organ transplant recipients (OTRs).99-
101 There is some evidence to suggest that posttransplantation immunosuppression may 
enhance melanoma progression leading to a worse outcome than for melanomas in the 
general population.102-105 Poorer melanoma-specific survival rates have been reported 
previously mainly in OTRs with thicker melanomas (2.01 – 4.0 mm)106, (1.5 – 3.0 mm)107, 
but recently also for thin melanomas with tumor thickness ≤1 mm.104  
 
1.2.3.2 Classification by subtype (clinical, histopathological, molecular) 
Melanomas have historically been divided into four major subtypes108-110, corresponding to 
the distribution of melanocytes within a horizontal/radial growth phase and a vertical growth 
phase, and based on clinical, epidemiological and histopathological features.111 A new 
classification, based on the integration of molecular, histological as well as clinical aspects 
has been launched and some of the former subtypes could be associated with specific genetic 
alterations, recently reviewed by Bastian.112  
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Table 3 outlines the main melanoma types and the emerging new classification.91, 112 
 
Table 3. Melanoma classification of the main types 
 
 
WHO classification69 
 
 
Emerging classification 
 
Major clinical and histological subtypes 
Primary 
oncogenic 
alteration 
 
Anatomic site and age 
distribution 
Superficial 
spreading 
melanoma 
(SSM) 
Mainly horizontal/ radial growth phase before 
vertical growth phase develops, pagetoid 
spread of atypical melanocytes within the 
epidermis. Association with a melanocytic 
nevus is common. 
Lentiginous melanoma and mainly nested 
melanoma113, 114 are considered SSM 
subtypes. 
BRAF 70% 
NRAS 15% 
 
Melanoma of intermittently 
sun-exposed skin called 
non-cumulative sun-
induced damage melanoma 
(Non-CSD melanoma) 
3rd to 6th decade 
Lentigo 
maligna 
melanoma 
(LMM) 
Not well-circumscribed lentiginous growth of 
atypical melanocytes in the epidermis, 
continuous proliferation of single cells as well 
as nests are common. 
KIT 10-
28%, 
NRAS 15% 
Cumulative sun–induced 
damage melanoma (CSD 
melanoma) 
7th decade and later 
Acral 
lentiginous 
melanoma 
(ALM) 
The lentiginous growth pattern prevails during 
the early phase. This type is more common 
among patients of Asian, Hispanic and African 
origin. 
KIT 15%, 
BRAF 
15%, 
NRAS 15% 
Acral sites such as palms, 
soles, and nail apparatus 
6th decade and later 
Nodular 
melanoma 
(NM) 
Invasive portion, i.e. the vertical growth phase, 
dominates in NM, with often only little upward 
spread, mainly in the epidermis overlying the 
invasive portion. 
No specific 
mutations 
Any site. 
Very rapid tumor 
progression, probably 
representing a final 
common pathway of other 
melanoma types.  
 
 
1.2.3.3 BRAF and other somatic mutations in melanoma 
In melanomas, BRAF mutations have been linked to clinical characteristics such as younger 
age, clinical/histological SSM subtype and localization on intermittently sun exposed sites.112 
BRAF mutations have also been detected in sporadic nevi and in nevi histologically adjacent 
to melanomas.115 BRAF mutations are now considered an early somatic, potentially initiating 
event112 but not sufficient for progression to melanoma116; a phenomenon called onocogene-
induced senescence.117 A large percentage of all melanomas (40 – 60%) have been shown to 
carry an activating mutation in the BRAF gene V600E, which has opened new therapeutic 
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possibilities. However, side effects of inhibiting BRAF have been the development of 
multiple verrucous squamous skin tumors, some with characteristics of SCC as well as new 
wild-type BRAF melanomas.96, 118 In a case report on eruptive nevi in a patient treated with 
the antimetabolite 6-mercaptopurine, due to ulcerative colitis, 85% of the analyzed nevi 
carried the activating BRAF V600E mutation.119 In an investigation of melanomas and nevi 
in OTRs, BRAF mutations were present in lower numbers compared to non-transplanted 
controls, 45% versus 64%, respectively.120 These findings suggest a possible link between 
immunosuppression and eruptive as well as sporadic nevi and melanomas, although 
melanoma-driving mechanisms in OTRs may also depend on other mutations than BRAF.120  
Certain other initiating, gain of function, mutations in potential oncogenes are listed in Table 
3. However, in the transition to the next progression stage, secondary oncogenic events, i.e. 
loss and gain of functional mutations, in certain genes like CDKN2A, p53, BAP1, PTEN, 
NF1, CDK4, TERT, XP, MITF, MC1R, POT1 (some of these are also known melanoma 
predisposing germline mutations, see Table 7) are vital.112  
 
1.2.3.4 Melanoma histology in OTRs 
There are only few studies that have analyzed histological characteristics of melanomas 
among OTRs. Commonly, the superficial spreading melanoma subtype (SSM) has been more 
frequently associated with a pre-existing melanocytic nevus, i.e. dysplastic/atypical (DN) or 
common/ordinary type.106, 121, 122 Another feature, which has been assessed histologically in 
melanoma, is the inflammatory reaction to the tumor: so-called tumor-infiltrating 
lymphocytes (TILs). It can be categorized as absent, sparse or brisk/abundant.123 The 
independent prognostic significance of TILs in melanomas in general remains controversial, 
but some studies have correlated a so-called brisk pattern with a favorable prognosis123-125, 
although others have failed to demonstrate such an association.126, 127 In posttransplantation 
melanomas only two studies have assessed TILs, showing that a sparse or absent lymphocyte 
infiltrate correlated with worse survival.121, 122  
 
1.2.3.5 Prognosis – staging in general 
The TNM classification system for melanoma is maintained by the American Joint 
Committee on Cancer (AJCC)128 and the Union for International Cancer Control.129 It 
combines clinical and surgical as well as pathological findings concerning the tumor (T), 
lymph nodes (N) and metastasis (M). The TNM staging system is a tool for clinicians to 
evaluate tumor burden and to determine treatment.  
Population-based survival studies under the auspice of the American Joint Committee on 
Cancer130, 131, and in Sweden by the Melanoma Study group93, 126, 132-134, have verified that 
millimeter thickness according to Breslow135 and ulceration136, 137 are the most powerful 
independent prognostic factors in localized melanoma. The prognostic impact of Clark’s 
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level138, has become less clear, in part probably due to difficulty in differentiating level III 
versus level IV melanomas. This is why Clark’s level has been replaced by presence of 
mitoses in the invasive component, especially in thin melanomas, i.e. ≤1.0 mm thickness, 
according to the latest AJCC staging classification.131, 139 Considering systemic spread, 
important factors are number of lymph node metastases and type of remote metastasis.  
 
In Table 4, the pathological and clinical tumor stages of melanoma are outlined. 
Table 4. Pathological and clinical staging of melanoma (TNM) 
 
Pathological 
T-classification 
Thickness (mm) Ulceration/ 
Mitosis 
10 year survival 
in Sweden140 
T1 ≤1.0 a: no ulceration, no mitosis;           
b: with ulceration or at least  
1 mitosis 
99% – 83% 
T2 1.01 – 2.0 a: no ulceration                              
b: with ulceration 
87% – 75% 
T3 2.01 – 4.0 a/b as above 73% – 59% 
T4 ≥4.01 a/b as above 66% – 45% 
Clinical stage 
 
pT stage Disease spread 
I T1 – T2a Localized: T1-2 N0 M0 
II T2b – T4b Localized: T2-4 N0 M0 
III Any T Lymph node(s): TxN1-3 M0 
IV Any T Other organs: Tx Nx M1 
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1.2.4 Rare skin cancer types 
 
In Table 5 rare skin cancer types relevant in OTRs are listed 
Table 5. Rare skin cancer types in OTRs 
 
Name Etiology Characteristics 
Kaposi’s 
sarcoma 
(KS) 
HHV8 
Malignant endothelial/ vascular tumor. Four types: classic (sporadic), African 
(endemic), AIDS-associated and transplant or immunosuppression-associated 
(iatrogenic).141 
 
More common in males (males to females 9: 1) and in certain populations, i.e. in 
Africa and in southern European countries mainly around the Mediterranean Sea 
(advocating a genetic susceptibility independent of typical immunosuppression).  
AIDS defining disease with higher risk of lymphoma.141, 142  
 
In Sweden KS is uncommon, but mainly develops in older males.143  
KS in OTRs 
Up to 5.7% of all cancers posttransplantation are KS, relative risks vary according to HHV8 
prevalence in the general population: 84 – 500-fold increased6, 144; UK (17-fold)12 and USA (61-
fold).13  
In Sweden risk was 39-fold increased compared to the general population (7 cases and the 
majority in males).14 
Merkel cells 
carcinoma 
(MCC)144 
 
PolyomaV 
virus: 
MCPyV37, 
present in 
60-90% in 
MCCs 
Derived from epidermal Merkel cells (type of neuroendocrine cell), tumor cells have 
a distinct immunohistochemical reactive staining pattern with, e.g. cytokeratin 20 
(CK20). 
Highly aggressive, poor prognosis and most common in older patients. 
  
Very rare tumor in Sweden; the incidence rate was 0.4 per 1 million.145 
 
MCPyV has also been detected in KCs, seborrheic keratoses and common warts, 
due to blood borne transfer through monocytes, which are considered a reservoir 
for MCPyV 
MCC in 
OTRs 
66-fold increased in a study from Finland146 and 65-fold in Sweden14 and just recently 24-fold in a 
large study from the USA147, in which synergistic effects of older age, long-term drug-induced 
immunosuppression and UVR are proposed. 
Adnexal or 
appendageal 
skin tumors 
(AST) 
Multiple 
factors 
Heterogeneous group: differentiating towards one or more epithelial adnexal 
structures69: -apocrine or eccrine, -follicular and -sebaceous differentiation. 
 
Benign and malignant counterparts exist for most of these tumor types. Difficult 
classification, due to overlapping differentiation features.  
 
Adnexal carcinomas vary in aggressiveness and etiology; some are especially 
common in the context of a genetic predisposition, e.g. Muir Torre syndrome.148  
Immunohistochemical and molecular typing are important tools in improving the 
understanding of the etiology and pathogenesis of ASTs.149 
AST in OTRs 
Population-based estimates in OTRs hardly exist, in study 2 a 40-fold increased risk was found.14 
Large variability of adnexal tumors in OTRs was described in a UK study150: 10 carcinomas out 
of 23 (43% versus 4% in immunocompetent patients) were found in 3% of kidney OTRs. Adnexal 
carcinomas were mainly located on the head-neck (74%) and the main types consisted of 
eccrine and sebaceous differentiated carcinomas.151  
 
Occasional malignant ASTs, mainly sebaceous carcinomas28, 31, 52, 53, 58, 144, have been reported. 
The possibility of an underlying genetic predisposition, i.e. an occult syndrome, cannot be ruled 
out, and neither can a correlation with the state of immunosuppression be excluded. 
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1.3 ETIOLOGICAL FACTORS OF SKIN CANCER IN OTR 
The term cancer encompasses a complex collection of diseases in different organs. The 
mechanisms that cause cancer contain both environmental and genetic factors, and the 
transformation of a normal to a malignant cell is often described as a multistep process. Just 
recently, Vogelstein and Tomasetti152 launched a new concept for the variation of cancer risk 
in different organs. The lifetime risk of developing cancer was strongly dependent of the 
assumed number of cell divisions in long-lived stem cells in different tissues. For example in 
the skin, both melanocytes and basal keratinocytes are exposed to the sun, but melanomas are 
much less common than basal cell carcinomas. The authors conclude that this difference in 
lifetime risk is due to the fact that epidermal cells undergo far more cell divisions than 
melanocytes.152  
According to Hanahan and Weinberg153, most cancers share 6 hallmarks: self-sufficiency in 
growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis. Four further 
“emerging” hallmarks are genomic instability and inflammation, which foster other hallmark 
functions, but also reprograming of energy metabolism and evading immune destruction.154 
In the stepwise process of cancer development, cancer cells acquire progressive genomic 
instability and increasing rate of mutations facilitates hallmarks to evolve. Cancer is viewed 
as highly heterogeneous and complex, also requiring normal cells that contribute to reciprocal 
interactions between malignant cells and the surrounding dynamic microenvironment.154, 155  
Pathogenic mechanisms of skin cancer are set in motion by underlying etiologic causes, 
triggered by certain risk factors, some determined by the environment and others by the host. 
Some of these can be controlled and allow the disease to be attenuated or even prevented. In 
OTRs, the drug-induced inhibited immune surveillance in combination with direct and/or 
indirect effects exerted by immunosuppressive drugs, of UV radiation, and of possible viral 
infection (HPV), can serve as a sufficient explanation for the increased incidence of different 
types of skin cancer. A strong argument for these combinatory effects is evidence that 
reduction of skin cancer burden can be achieved through complete withdrawal but also 
through reduction of immunosuppression.78, 156  
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Figure 2 summarizes the multifactorial pathogenesis of skin cancer in OTRs: 
Immunosuppressive medication, ultraviolet radiation (UVR), HPV infection, suppressed 
immune system, and host factors. 
 
1.3.1 Immunosuppressive medication 
There is strong evidence that the state of drug-induced immunosuppression confers a 
considerable long-term risk for the development of posttransplantation diseases including 
malignancies. The ideal goal of drug-induced immunosuppression is to maintain organ 
function at the expense of minimal adverse effects. From the beginning of modern 
transplantation medicine the focus has been on preventing acute rejection, but since the 
introduction of powerful immunosuppressive drugs, focus has more and more shifted towards 
developing strategies for preventing chronic rejection and side effects from long-term drug 
use. Such risks are infections, diabetes, nephrotoxicity, and cardiovascular disease due to 
hypertension and hyperlipidemia; a great deal of effort is invested in reducing their effects157, 
however, the long-term risk of posttransplantation malignancy remains.27, 157, 158 
1.3.1.1 Immunosuppressive medication and skin cancer 
The assessment of risk of posttransplantation cancer development is challenging, because of 
multidrug regimen, which make the identification of a specific drug nearly impossible. Some 
studies have delivered evidence that Azathioprine (AZA), Cyclosporine A (CsA), Tacrolimus 
(Tac), and corticosteroids (Cs) can be associated with a higher risk of cancer.22, 159, 160 There 
is mounting evidence that the group of calcineurin inhibitors (CNI), i.e. CsA and Tac, and 
also AZA mainly contribute to skin carcinogenesis in OTRs. This is due to both direct and 
indirect mechanisms: by decreased immune surveillance, promotion of tumor vascularization, 
Figure 2. Multifactorial pathogenesis of skin 
cancer in OTRs 
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Adapted with permission from Dr. Claas Ulrich, Charité, Berlin, Gemany 
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cancer cell invasiveness and progressive DNA damage and/or DNA repair inhibition.21, 161 
Inhibitors of the mammalian target of rapamycin (mTOR inhibitors), on the other hand, can 
both suppress and inhibit tumor development. Therefore an early switch to mTOR inhibitors, 
before multiple SCCs develop, but also after development of other skin cancers as well as 
non-skin cancers, is advocated nowadays.21, 162-165  
Often, kidney OTRs with a graft coming from a living and HLA-identical donor require 
lower dosages of immunosuppressive drugs compared to OTRs with a graft from a deceased 
donor.166, 167 Heart and lung recipients often receive higher dosages, due to higher 
cautiousness in preventing acute rejection, which is possibly fatal.168 Drug-induced 
immunosuppression in liver recipients is usually lower, due to lesser immunogenicity of this 
organ.1, 6, 12, 169 Choice of combinations of drug regimen is dependent on graft type, patient 
prerequisites, e.g. gender and age, but also on local routines, recommendations and 
preferences of the transplant program. In general, the goal nowadays is to reduce and 
ultimately completely remove Cs as a treatment and also of reduction of CNI with time.170  
Table 6 gives an overview of most commonly used maintenance immunosuppressive drugs in 
OTRs. Drugs that are mainly applied for the short period of induction treatment, e.g. antibody 
preparations directed at lymphocytes or cytokines, are not included.  
 
Table 6. Immunosuppressive medications used for maintenance 
prophylaxis against rejection23, 171, 172 
Agent/ 
Drug 
Mechanism 
of action 
Toxicity 
 and side effects 
Believed mechanisms of  
skin cancer formation 
Cyclosporine 
(CsA) 
Introduction in 
Sweden early 
1980s, combined 
with Cs, AZA and 
MMF, great 
variability in bio-
availability, which 
has improved with 
the Neoral 
formulation 
Binds to cyclophilin 
and inhibits 
calcineurin dependent 
transcription of 
cytokine genes (via 
NF-AT), particularly 
IL2. Enhances TGF-
b, inhibits mainly T-
cell, but also B-cell 
proliferation. 
Gingival hyperplasia, 
hirsutism, constipation, 
nephrotoxicity, 
hypertension, tremor, 
headache, paresthesias, 
flushing, chronic allograft 
nephropathy due to fibrosis 
and cardiovascular 
diseases, less frequent 
diabetes than Tac. 
Aberrant p53 signaling and 
down-regulation of DNA 
repair mechanisms of UVR 
induced mutations in 
keratinocytes, leading to a 
Xeroderma pigmentosum-like 
phenotype.26 
Also other indirect and direct 
tumor promoting effects.159, 
161  
Tacrolimus (Tac) 
Introduction in 
Sweden during 
early 2000s, 
combined with 
MMF, Cs, better 
bioavailability. Tac 
is currently the 
main used CNI.  
Binds to FK-binding 
protein, inhibits 
calcineurin dependent 
transcription; the 
mechanism is similar 
to CsA.  
Less cosmetic side effects 
(no hirsutism), but 
paresthesias, and glucose 
intolerance, which can lead 
to diabetes. 20% less 
rejection episodes 
compared to CsA. 
Nephrotoxicity, 
hypertension, 
cardiovascular diseases, 
tremor, headache, flushing.  
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Table 6 continued. 
Agent/ 
Drug 
Mechanism 
of action 
Toxicity 
 and side effects 
Believed mechanisms of  
skin cancer formation 
Azathioprine 
(AZA) 
Available in 
Sweden since the 
1960s’, in 
combination with 
Cs, MMF, CNI or 
mTOR. 
Antimetabolite, 
inhibits purine ring 
biosynthesis 
(guanosine), leads to 
decreasing synthesis 
of DNA and RNA, 
inhibits thereby T- 
and B-cells, Natural 
killer cells (NK), and 
macrophages. 
Unspecific action on all 
replicating cells.  
Macrocytic anemia, 
leukopenia, pancreatitis, 
cholestasis with jaundice, 
hepatitis.  
Not efficient against acute 
rejection. 
Accumulation of 6-
thioguanine in keratinocytes 
increases photosensitivity to 
normal UV light (selective to 
UVA), leading to direct and 
indirect UV induced DNA 
damage.24  
Also other indirect and direct 
tumor promoting effects.159  
Mycophenolate 
mofetil (MMF) 
Introduction in 
Sweden from late 
1990s, MMF has 
replaced AZA, in 
combination with 
CsA/Tac, and Cs. 
Antimetabolite, 
inhibits the de novo 
pathway for guanine 
nucleotide 
biosynthesis, needed 
for T- and B-cell 
synthesis, promotes 
apoptosis, 
suppresses dendritic 
cell maturation. 
Can cause gastrointestinal 
distress, leukopenia. 
Not known, possibly a 
somewhat lower risk of 
cancer.173  
In heart OTRs MMF intake 
was associated with a higher 
risk of BCC.58 
Sirolimus (mTOR 
inhibitor) 
Introduction in 
Sweden from later 
2000s, combined 
with MMF, AZA, 
and Cs. Long 
halftime, therefore 
difficult to steer. 
Binds to FK-binding 
protein, mTOR 
pathway inhibition, 
inhibits IL2– and IL6–
driven events, mTOR 
signaling is necessary 
for cell cycle 
progression, cell 
growth, lymphocyte 
proliferation and 
antibody production. 
Important for cell 
survival and 
angiogenesis. 
Hypertriglyceridemia, 
thrombocytopenia, 
leukopenia, proteinuria, 
nausea, potentially fatal 
interstitial pneumonitis and 
aseptic pneumonia (has 
become a lesser problem 
lately, and is reversible in 
most cases), less 
nephrotoxic. Risk of early 
vascular thrombosis in liver 
OTRs. Proteinuria and high 
kreatinine levels are a 
contraindication to mTOR 
inhibition. 
Effective antitumor agent, 
inhibits angiogenesis, inhibits 
tumor metastasis, and lacks 
the inhibiting effect on DNA 
repair of UVR induced 
mutations. Believed to inhibit 
UVB activation of metallo-
proteinases that may promote 
skin cancer formation174 
reduces both SCC and BCC 
development in OTRs.162-164 
Cortico-steroids 
(Cs) 
Oldest IS, in 
Sweden available 
since the 1950s 
Inhibition of pro 
inflammatory 
cytokines through 
NFkB and AP1. 
Multiple effects on 
antigen presentation/ 
dendritic cell function, 
and reduction of 
lymphocyte 
activation.175 
Cushingoid habitus, 
glucose intolerance, 
hyperlipidemia, 
hypertension, cataracts, 
myopathy, osteoporosis. 
Not known, maybe through 
down-regulation of immune 
surveillance. 
 
IL2 interleukin 2 (cytokine), TGF-b transforming growth factor beta, CNI calcineurin inhibitor, NF-AT nuclear factor of 
Activated T-cells (transcription factor), FK-binding protein (member of the immunophiline protein family and interacts with 
TGF-b), NFkB nuclear factor-kappa of activated B-cells (transcription factor), AP1 activating protein (transcription factor) 
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1.3.1.2 Other conditions of immunosuppression and risk of skin cancer 
HIV and drug-induced immunosuppressed patients are predominantly immunodeficient in T- 
and B-lymphocyte types, which means that these patients still have a residual capability for 
immunological defense against cancer. This is believed to be mounted in part by natural killer 
cells (NK) and other innate immune cells.154 Data from genetic-, disease-, and drug-induced 
immunosuppression are relatively consistent in two conclusions: Firstly, immunosuppression 
is associated with increased risk of certain types of cancer, and secondly, a significant 
proportion of these cancers are associated with viral infections.176, 177  
HIV patients with low levels of CD4 helper T-cells, reviewed by Corthay178, are at an 
increasing risk of developing one or more of the AIDS-defining malignancies, i.e. Kaposi’s 
sarcoma (KS), non-Hodgkin lymphoma (NHL), and cervical cancer. The incidence of the 
AIDS-defining malignancies has sharply decreased since the introduction of highly active 
anti-retroviral therapy in the mid 1990s.179, 180 However, risk of certain other cancer types, for 
example skin cancer (KCs), is still approximately 4-fold increased.36, 181, 182 Hence, the 
remaining risk of cancer might in part be attributed to an immune modulatory effect of the 
HIV virus itself 183, to the anti-retroviral drugs, or to other factors.179 
Other conditions of drug-induced immunosuppression are for example rheumatoid arthritis 
and inflammatory bowel syndrome. These conditions are often treated with different types of 
immunosuppressive drugs (Table 6). Additionally, inhibitors of tumor necrosis factor-alpha 
and methotrexate are also utilized. No increased risk of cancer was found in patients with 
rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitors.184, 185 On the other 
hand, a 4-fold increased risk of mainly lymphoma and skin cancer (SCC and BCC) was noted 
in patients with inflammatory bowel syndrome taking AZA in comparison to those treated 
with tumor necrosis factor-alpha inhibitors.186 However, in a recent study, risk of skin cancer 
was unrelated to type of therapy (AZA, methotrexate, tumor necrosis factor-alpha 
inhibitors).187 The difference in cancer risk between patients with inflammatory bowel 
syndrome and rheumatoid arthritis might in part be due to differing dosages and drug 
combinations.  
In patients with lympho-proliferative disorders, especially NHL, the reported risk of 
contracting any cancer was approximately 2-fold increased and risk of melanoma was up to 
2.4-fold increased.102 Although, according to a Swedish population-based study, risk of 
melanoma was not significantly increased in patients with NHL.188 
 
1.3.2 Ultraviolet radiation (UVR) 
The most relevant environmental carcinogenic agent regarding skin is ultraviolet radiation 
(UVR), which is part of the electromagnetic radiation emitted by the sun. UVR contains 
UVA (315 – 400 nm), UVB (280 – 315 nm) and UVC (100 – 280), the latter and most of 
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UVB are blocked by the stratospheric ozone layer. The remaining UVB (5%) and nearly all 
UVA (95%) reaches the earth’s surface, and both contribute to skin carcinogenesis.96, 189 
The epidermis absorbs most of the high energetic, short wave UVB, but some also reaches 
the papillary dermis. UVA is the long and low energetic wavelength that can penetrate deeper 
and reach the papillary and the upper reticular dermis. 190 UVB and UVA are responsible for 
causing tanning (UVB persistent and UVA also immediate pigmentation) and elastin damage 
(wrinkling).190, 191 UVB is the most potent carcinogen and 1,000-fold more effective in 
causing sunburns than UVA. UVB and UVA can transfer its energy directly to the DNA in 
stem cells of the basal epidermis, but also to the dermis192-194, leading to the formation of UV 
photoproducts (UV signature), i.e. cyclobutane pyrimidine dimers and pyrimidine-6-4-
pyrimidone photoproducts. The most frequently induced cyclobutane pyrimidine dimers are 
thymidine residuals that cross-bind to form thymidine-thymidine dimers. These are mainly 
induced by UVB with some contribution of UVA.96, 190, 192, 193 Once formed, cyclobutane 
pyrimidine dimers are very stable and can persist for extended periods of time in the DNA, 
with the risk of altering DNA transcription, unless they are recognized and removed by 
certain DNA repair enzymes.195 If these repair mechanisms fail in DNA of epidermal-, 
follicular- and in melanocyte- stem cells, permanent mutations with risk of clonal expansion 
and tumor formation occur.  
UVA also leads to indirect DNA damage by the formation of so-called reactive oxygen 
species.190 In experimental studies UVA induced DNA damage took longer time to repair and 
speculatively this is due to a less efficient DNA repair system compared to UVB induced 
DNA repair.193 From both in vitro and in vivo studies on melanocytes and melanoma cells, it 
is nowadays believed that only UVB is capable of initiating melanoma, while both UVA and 
UVB are involved in its progression.196 Further evidence for the role of UVA in the etiology 
of melanoma and BCC come from studies on the late effect of artificial UVR tanning devices 
(sun beds), which mainly produce UVA. Their use has been associated with an increased risk 
of subsequent melanoma and also BCC.45, 96, 189, 196, 197 Just recently, Premi et al. showed that 
more than 50% of “dark CPD” formation in melanocytes and in keratinocytes appeared >3 
hours following UVA exposure, rendering melanocytes and keratinocytes potentially 
carcinogenic. According to the authors, substances such as topical vitamin E in after-sun 
lotions could block this delayed carcinogenic effect, if applied within this timeframe.198  
Many UVR induced mutations affect the tumor-suppressor gene p53. Normally, there is little 
p53 protein in the cell, but in response to UV damage, high levels of p53 are induced. High 
p53 leads to cell cycle arrest, allowing cellular repair to remove DNA lesions before DNA 
synthesis and mitosis takes place. When DNA damage is abundant, apoptosis is induced to 
eliminate these mutated cells.190, 199 In skin carcinogenesis, mutations in p53 appear to 
develop early with mutant clones already found in normal appearing sun-exposed skin, in 
pre-cancerous AKs, and within a large proportion of SCCs and BCCs. The phenomenon of 
altered p53 in skin adjacent to AKs and tumors is called “field cancerization”. It is believed 
that clonal expansion is due to a tumor-promoting microenvironment, whereas in normal 
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appearing skin tumor development is held at stake by the tumor-suppressing effects of the 
surrounding tissue. 200-202 
 
1.3.3 Infection with human papilloma virus (HPV) 
OTRs often develop many viral warts/ verrucae, i.e. benign lesions due to infection with HPV 
of genus beta-papillomavirus (β-HPV). Many β-HPV types are ubiquitous in the general 
population and frequently establish themselves already during the first weeks of life with hair 
follicles being regarded as the natural reservoir.203 Furthermore, β-HPV DNA has been 
detected in normal appearing skin204, as well as on the surface of different types of squamous 
skin lesions, but not in the underlying portion.205  
Incidence and severity of warts are related to the degree and length of immunosuppression 
and approximately 90% of OTRs have developed warts after more than five years of 
immunosuppression.1, 52, 53 In OTRs with warts a 2-fold higher risk of SCC has been observed 
compared to OTRs without warts.206 There is often little correlation between the clinical 
impression of hyperkeratotic, verrucous lesions and their histopathological appearances in 
OTRs.207 In the study referred to, features indicative of a viral etiology were associated with 
certain architectural and cytological characteristics. With emerging dysplasia and 
invasiveness these viral features diminished, although DNA of oncogenic β-HPV types 5 and 
8 could still be traced in >60% of the lesions. Many studies have investigated the presence of 
β-HPV DNA in SCCs with prevalence rates of up to 90% and generally somewhat higher in 
OTRs compared to immunocompetent patients.203, 208-211  
The genomic organization of HPV is divided into 3 regions, a non-coding, an early and a late 
genomic region. The early proteins (E1- E7) are required for viral DNA replication and 
transcription; E6 and E7 are considered major oncoproteins.212 The oncogenic functions of β-
HPV E6 proteins are mediated through inhibition of apoptosis of UV-damaged cells213, 
interference with DNA damage repair214, 215, and influence on normal keratinocyte 
differentiation.216, 217 The E7 protein is also able to modulate the differentiation profile of 
keratinocytes and is able to induce cell invasion.218 Further, it has been reported that 
oncogenic β-HPV is able to induce immunosuppression by inhibition of antigen-presenting 
cells.219 
Current research indicates that oncogenic β-HPV promotes the initial stages of keratinocytic 
carcinogenesis, i.e. the precancerous stage, but is not required for maintenance of the 
transformed phenotypes, i.e. the invasive SCCs.209, 220, 221 High viral DNA loads of β-HPV are 
therefore considered a possible co-factor in SCC development, in OTRs and in 
immunocompetent patients 222, as opposed to the established role of certain HPV of genus 
alpha-papillomavirus in genital and oropharyngeal cancers.223  
Although effective bivalent, quadrivalent and soon even nonavalent224 vaccines against α-
HPV infection exist for the prevention of genital cancer, they have no effect on infections 
 30 
with β-HPV. Currently, new vaccine formulations for the prevention of warts in children, and 
consequently also for the prevention of SCCs in OTRs are under evaluation.225-227  
1.3.4 Inflammation and the tumor microenvironment in SCC 
In cancers accumulated “driver” mutations and a high rate of “passenger” mutations are 
believed to be recognized as tumor-specific antigens by the immune systems’ adaptive arm; 
either by T-cells with the help of antigen-presenting cells (APCs) and also by B-cells.178 All 
solid tumors are infiltrated by a variety of immune cells and for some types of human cancers 
a correlation between type and density of different immune cells with clinical outcome has 
been reported.178 However, some tumor-associated inflammation has emerged as having an 
unanticipated, paradoxical effect of enhancing carcinogenesis and progression. This helps 
evolving tumors to acquire hallmark capabilities.154 Inflammation can contribute to tumor 
development by supplying growth, survival, and pro-angiogenic factors, and also by active 
suppression of the local immune response, permitting non-immunogenic tumor cells to evade 
immune destruction, which is one of the hallmarks of cancer.154  
The role of the innate immune system in tumor immune surveillance is so far unclear. It is the 
first line of defence against pathogens and reacts immediately to conserved microbial 
antigens such as lipopolysaccharide, but has no memory function.175 The main components 
are physical barriers, such as skin and mucosal epithelia. It also includes antimicrobial 
peptides, so-called pattern recognition receptors such as toll-like-receptors, the complement 
system, cytokines, mast cells, macrophages, granulocytes, natural killer cells (NK cells) and 
thrombocytes.175, 228 From tumor models in mice it is known that deficiencies in quantity and 
function of CD8 cytotoxic T-cells, CD4 helper T-cells (type 1), or NK cells each led to 
demonstrable increases in tumor incidence. These findings indicate that both the innate and 
adaptive arms of the immune system contribute to tumor surveillance.154, 178 Macrophages 
may help to create a tumor friendly environment by facilitating angiogenesis and breakdown 
of extra cellular matrix and thereby promoting tumor cell motility, leading to progression and 
metastasis.229 Also, current evidence supports an accessory role of mast cells during the 
development and progression of mainly BCC and melanoma, with some role also in SCC.230 
Mast cell density was higher in aggressive SCCs, suggesting that mast cells contribute to a 
permissive tumor environment and may enhance metastasis.230  
Some evidence for a role of the innate immune system in skin cancer stem from the effective 
topical treatment of superficial skin tumors, including AKs and BCCs, with a synthetic 
agonist to the toll-like-receptor 7, imiquimod. The treatment triggers the release of cytokines 
such as interferon-gamma, which helps destroy cancer cells. The underlying effect is related 
to a shift towards a more tumor-suppressive microenvironment.67, 231, 232 Topical treatment 
with anti-inflammatory drugs like diclofenac has a similar effect, which is attributed to 
inhibition of cyclo-oxygenase-2 and the induction of apoptosis.67, 233 Despite systemic 
immunosuppression, OTRs were able to recruit an equivalent immune response upon 
treatment with imiquimod, leading to tumor clearance.234-236 Some further evidence of a 
contribution of the innate immune system in skin cancer may be derived from a study on gene 
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expression (mRNA) levels of toll-like-receptors. Mühleisen et al. studied these signaling 
molecules and other antimicrobial peptides in SCCs and BCCs from both OTRs and non-
transplanted controls.237 They found distinct differences of innate immune gene expression in 
SCC compared to normal skin and BCC, but differences between OTRs and controls were 
not consistently obvious. Also, it was unclear whether gene expression was tumor-intrinsic or 
induced by the tumor environment. The authors interpret their results as an indication for a 
role of the innate immune system in skin carcinogenesis.237  
Antigen-presenting cells (APCs) function as the bridge between the innate and adaptive 
immune system. APCs ingest, process and present antigen bound to molecules of the major 
histocompatibility complex class II (MHC II), and are partly derived from circulating 
monocyte precursors.175 APCs of the dermis as well as the epidermis have potent stimulatory 
capacity of naïve and memory T-cells in local lymph nodes. However, sometimes stimulation 
leads to supposedly adverse effect of inhibiting anti-tumor T-cell function and proliferation. 
The development of tumor promoting regulatory T-cells (T-regs), as shown in a tumor model 
in mice.238 Even B-lymphocytes, which are uncommon in normal skin239, seem to play an 
important role in establishing an adaptive immune response, as they interact with APCs and 
produce antibodies. In mice, which were deficient of mature B- and T-cells, skin cancer 
developed first after adoptive transfer of B-lymphocytes.240 APCs are a heterogeneous cell 
population consisting of dendritic cells (DCs) and macrophages; DCs can be divided into 
epidermal Langerhans cells, myeloid and plasmacytoid DCs.228 
The principle components of the adaptive immune system are lymphocytes (T-cells and B-
cells), plasma cells and antibodies. Adaptive immune response exhibits great diversity and 
memory function, and can bring about an enhanced and fast response after repeated contact 
with the same antigen.175 Lymphocytes are sub-grouped according to the expression of 
surface proteins called clusters of differentiation (CD); T-cells are CD3 positive and B-cells 
are CD20 positive. T-cells can be further subdivided into CD4 helper T-cells and CD8 
cytotoxic T-cells. Naïve T-cells require antigen-presenting cells (APCs) to evoke immune 
responses. Only the T-cell, either CD4 helper T-cell or CD8 cytotoxic T-cell, which 
recognizes its unique antigen presented by an APC together with MHC on its surface can 
become activated and expand, i.e. clonal expansion; this is called cell-mediated immunity.175, 
228 Besides the specific antigen, activation of T-cells requires co-stimulatory signals and a 
cytokine environment delivered by APCs. Mature B-cells can recognize naïve antigens 
directly, i.e. without T-cell or APC interaction and differentiate into plasma cells and produce 
antibodies. 
CD4 helper T-cells secrete cytokines in order to stimulate proliferation and differentiation of 
T-cells and APCs.175 They are sub-grouped depending on their capacity to produce different 
cytokines into type 1 and type 2 helper T-cells (Th1 and Th2) as well as into regulatory T-
cells (T-regs). The production and secretion of interleukin 4 (IL4) is attributed to Th2 cells, 
helping B-cells to mature into antibody producing plasma cells and activating eosinophils. 
The production of interferon-gamma is attributed to Th1 cells, helping macrophages and CD8 
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cytotoxic T-cells to activate and leading to a tumor-suppressive environment. Th2 cells are 
able to suppress Th1 mediated immune responses, and Th2 cells are also less susceptible to 
the suppressive activity of T-regs.241 The balance between Th1- and Th2-immune responses 
determines the type and efficacy of the cell-mediated immune response. 
Regulatory T-cells (T-regs) are another subgroup of helper T-cells. They express CD4, CD25 
and transcription factor FOXP3.242 T-regs control and inhibit specific immune reactions by 
other helper T-cells and by APCs with the effect that these helper T-cells do not activate, 
differentiate and proliferate. In consequence this leads to inactivity of CD8 cytotoxic T-cells, 
because of no or low interferon-gamma, and also to inactivity of macrophages and B-cells, 
which results in diminished differentiation to plasma cells and formation of antibodies. T-regs 
are able to discriminate between bad, meaning self-reactive helper T-cells, that should be 
suppressed (for tolerance) and good, meaning for example virus- or tumor-specific helper T-
cells that should not be suppressed. If this discrimination is faulty, the host will succumb to 
microbial infection or cancer.242 
Solid tumors are usually infiltrated by a variety of immune cells and among all helper T-cells, 
those of Th1 subtype seem to be an advantageous for the host’s survival in certain internal 
cancer types (e.g. in liver, breast, and colorectal cancer).178 If the balance between desirable 
tumor-rejecting immune responses Th1 and undesirable tumor-promoting inflammatory 
responses Th2 is tipped over towards Th2, then, immune cells around tumors exhibit 
increased levels of mainly Th2 helper T-cells, macrophages, i.e. tumor-associated 
macrophages, also referred to as type-2-macrophages, T-regs (which can suppress action of 
CD8 cytotoxic T-cells) and possibly also mast cells.  
The cellular composition of different inflammatory cells engaged in the microenvironment of 
SCCs in normal, i.e. non-transplanted patients, has been studied with the help of 
immunohistochemistry.239, 243, 244 In summary, these reports show a dominance of T-cells, 
with a CD4 helper T-cell to CD8 cytotoxic T-cell ratio of approximately 2-4: 1. Also NK 
cells, macrophages, mast cells and granulocytes were present. Often no correlation between 
density or composition of the infiltrate and the tumor size, level of invasion or type of lesion 
(actinic keratosis, in-situ SCC or infiltrative SCC) was reported. For example, in human SCC, 
presence of CD8 cytotoxic T-cells expressing MHC class II antigen, was taken as an 
indication of specific T-cell activation towards tumor-antigen.244 
UVR induced immunosuppression should also be taken into account in the pathogenesis of 
SCC in general. It leads to diminishing antigen-presenting cell functions, for example by 
reduction of epidermal Langerhans cells, leading to insufficient antigen presentation in the 
lymph nodes. Also, UVR induces immunosuppressive cytokine production promoting a shift 
towards a more tumor-permissive microenvironment, i.e. Th2, resulting in decreased immune 
surveillance and in consequence tumor promotion.231, 245, 246  
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Figure 3 describes the balance of cell populations in the tumor microenvironment. 
 
1.3.5 Host factors 
Certain genetically determined factors are associated with a higher risk of skin cancer in 
general. The focus is specifically put on the association of clinical skin phenotypes, which 
determine UV susceptibility, and on predisposing conditions, for example family history of 
skin cancer, as well as on somatic aberrations in SCC, BCC, and melanoma.  
1.3.5.1 Skin phenotype - pigmentation and UVR susceptibility 
Fair-skinned patients with a propensity to sunburn are at increased risk for skin cancer. To 
shield epidermal DNA from UVR basal melanocytes produce and transfer melanin to 
surrounding keratinocytes for its distribution throughout the epidermis. Constitutional 
pigment formation varies according to race and reflects the basal level of melanin production. 
In fair-skinned individuals constitutive pigmentation is assessed through hair color, eye color 
and the presence of freckles. Facultative pigment formation reflects an individual’s ability to 
enhance melanin production following the exposure to UVR. The combination of 
constitutional and facultative pigmentation traits defines the clinical skin phenotype, 
elucidated by Fitzpatrick’s 6-level classification.247 Certain attributes, for example a fair skin 
phenotype (type I and II), blue, grey or green eye color, red or blond hair, a propensity to 
freckle or burn associate with a higher risk for all three types of skin cancer, reviewed by 
Binstock et al.248 More than 150 genes in the pigmentation pathway encode proteins, which 
determine the skin’s clinical phenotype. Small alterations, i.e. single-nucleotide 
polymorphisms, in genes of the pigmentation pathways, could be linked to higher risk of SCC 
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and BCC, and also to melanoma.249, 250 The most promising belong to the facultative 
pigmentation system and include the melanocortin-1 receptor (MC1R).248, 251 Alterations 
might lead to aberrations in the production of protective melanin. Also, several variants of the 
MC1R are highly correlated with red hair, poor tanning ability, freckles, and increased 
melanoma risk.96, 252  
Epidemiological and experimental data on UVR exposure patterns and skin cancer, 
summarized by Armstrong and Kricker191, as well as by Narayanan et al.190, strongly suggest 
that the mode of sun exposure over time is related to the pattern of skin cancer types later in 
life: 
• SCC and BCC incidence have a large latitude gradient, from north to south, while the 
gradient for melanoma is smaller 
• The total burden of all UVR exposure determines risk: in melanomas and BCCs 
intense intermittent exposure with burns during childhood, and in SCCs low intense 
chronic exposure 
• All skin cancer types are more common in fair-skinned individuals with no to 
moderate tanning ability; this association is stronger in SCC and BCC than in 
melanoma 
• SCCs develop mainly on the face, neck and the dorsum of the hands, in females also 
on the lower legs; BCCs are mainly seen on the face and neck, followed by the trunk; 
melanomas are more common on the trunk, followed by the face and neck, in females 
also on the extremities 
• Presence of AKs is more strongly associated with risk of SCC than with risk of BCC, 
and presence of melanocytic nevi is most strongly associated with risk of melanoma  
• Lastly, SCC and BCC development are mainly associated with UVB; melanoma 
development is associated with UVB as an initiator and with UVA as a promotor, 
reviewed by Mitchell and Fernandez196 
Also in OTRs, the risk of skin cancer, mainly analyzed for SCC, has been similarly 
associated with fair skin phenotypes (I and II) and blond hair color.206, 253 The study by 
Lindelöf et al. investigated whether a change in sun seeking behavior, under dialysis and after 
transplantation, influenced risk of SCC. The results showed that all OTRs had decreased sun 
exposure, but those with mainly skin phenotype I and II still developed SCCs. It therefore has 
to be assumed that much of the carcinogenic risk burden was already acquired before dialysis 
and transplantation and that SCC risk is more likely to be related to other factors, such as sun 
sensitivity.1, 206 The association of skin cancer risk with skin phenotype and eye color was 
generally stronger for SCC than for BCC in British and Australian OTRs.31, 254 
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1.3.5.2 Genotypes 
Known predisposing genetically determined conditions of skin cancer  
The knowledge of cancer predisposing genes that are important for the development of skin 
cancers, either of germ-line, i.e. can be passed to the next generation, or somatic, i.e. acquired 
(or both), has been expanding over the last few decades. Most of these mutations act as 
tumor-suppressor genes with abrogated genefunction, i.e. loss-of-function, and thereby lead 
to an increased cancer risk, while only a few act as enhancing, i.e. gain-of-function.255  
Table 7 gives an overview of the most important familial cancer syndromes. 
 
Table 7. Skin cancer predisposing syndromes 
Condition Genes Characteristics Variants 
Basal cell nevus 
syndrome155, 256-258 
Gorlin Syndrome 
Autosomal dominant 
 
PTCH1, PTCH2, 
SUFU 
Prevalence: 1: 
57,000 in the 
general population 
and 1: 200 in 
patients with multiple 
BCCs, and even 
higher in young 
patients with BCC. 
Large numbers of 
BCCs, already at young 
age, also odontogenic 
cysts, skeletal 
abnormalities, and a 
predisposition to other 
tumors such as 
medulloblastomas. 
Non-syndromic BCC 
susceptibility: multiple BCCs, 
mainly in male family 
members, of strictly unilateral 
BCCs, but also of truncal 
versus a non-truncal location, 
have been suggestive of 
somatic mosaicisms. 
Xeroderma 
pigmentosum (XP)259, 
260 
Autosomal recessive 
XPA-XPG 
Ineffective 
nucleotide excision 
repair mechanisms, 
leading to 
insufficient repair of 
UV induced 
alterations in the 
DNA. 
Extreme UV sensitivity 
and exceptionally high 
risk of SCC, BCC and 
melanoma with great 
risk of early death due 
to skin cancer. Also 
growth and mental 
retardation as well as 
congenital 
malformations. 
Compared with the 
population risk of skin 
cancer is 2,000 – 
10,000-fold increased. 
Heterozygosity is also a risk 
factor for mainly SCCs and 
BCCs, following excessive 
sun exposure. 
The less severe variant, XPV, 
(POLH), has normal DNA 
excision repair. Patients are 
photosensitive and at 
increased risk of skin cancer 
but lack features of 
retardation and 
malformations. 
 
  
 36 
Table 7 continued. Skin cancer predisposing syndromes 
Condition Genes Characteristics Variants 
Familial melanoma249, 
255, 261-265 
Approximately 10% of 
all melanomas are 
familial 
 
CDKN2A, CKD4, 
BAP1, POT1 
 
CDKN2A mutations 
have been detected in 
approximately 20-40% 
of the melanoma prone 
families around the 
world: Increased 
numbers of family 
members with multiple 
melanomas, onset at 
early age and higher 
frequency of pancreatic 
and lung cancer, and in 
some families 
association with 
melanocytic nevi.  
Non-CDKN2A familial 
melanoma: a simultaneous 
higher risk for SCCs and 
BCCs, which is believed to be 
associated with accumulation 
of low-risk melanoma 
susceptibility genes, some of 
which associated with 
multiple nevi or with 
pigmentation phenotype (for 
example MC1R). 
Li Fraumenti 
syndrome and Li 
Fraumenti-like 
syndrome (LFS)155, 266 
Autosomal dominant 
Clinically and 
genetically 
heterogeneous 
familial cancer 
syndromes, not all 
are located on the 
tumor-suppressor 
gene p53 
(chromosome 17). 
Early onset of tumors in 
a variety of organs, 
often already during 
childhood, including skin 
cancers. 
A distinct germ-line variant in 
the p53 gene, not related to 
LFS, has been recently 
associated with a 2-fold 
increased risk of BCC. 
Condition Characteristics 
Recessive dystrophic 
epidermolysis bullosa 
Autosomal recessive 
Severe skin disease characterized by skin fragility and blistering, resulting in 
mutilating scarring and contractures. It is associated with early development of 
aggressive and metastatic SCCs. 
Epidermodysplasia 
verruciformis 
Autosomal recessive 
Rare genodermatosis associated with high risk of SCCs, which is due to 
abnormal susceptibility and impaired cell-mediated immunity towards certain β-
HPV types, some with oncogenic potential, i.e. HPV types 5 and 8. 
Muir Torre syndrome 
(MTS) 
 
Autosomal dominant 
One sebaceous skin tumor and at least one visceral cancer are sufficient for 
MTS, also SCCs and keratoacanthomas can appear more often, a family history 
is not always apparent. 
MTS represents a subset of the cancer syndrome non-polyposis colorectal 
carcinoma (HNPCC), it is an inherited defect of DNA mismatch repair (MMR) 
gene, subsequent loss of the other allele leads to genetic instability knows as 
microsatellite instability (MSI), the two major MMR proteins are MSH2 and 
MLH1. 
Ferguson-Smith 
syndrome 
Autosomal dominant 
The multiple self-healing squamous epithelioma/keratoacanthomas syndrome 
has recently been linked to mutations of TGFBR1, a gene encoding a kinase 
receptor for transforming growth factors.  
Bazex syndrome 
X-linked dominant 
The follicular atrophoderma and BCC syndrome is associated with early onset 
BCC from the second decade 
Oculocutaneous 
albinism 
Autosomal recessive 
Four different kinds of mutations in genes controlling melanin production within 
melanocytes. High risk of SCC and BCC.  
Rombo syndrome 
Autosomal dominant Associated with early onset BCC from the third decade 
Hurriez syndrome 
Autosomal dominant Associated with atrophic fibrosis and keratoderma and an increased risk of SCCs 
 
155, 220, 255, 267 
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Somatic mutations in SCCs and BCCs 
SCCs develop in a multistep process with many genetic aberrations taking place in a 
seemingly uncontrolled way. Most SCCs are thought to develop from AKs, though most AKs 
do not progress to SCC, there is both histological and molecular evidence to support this 
hypothesis.70, 268-270 Many somatic changes commonly found in SCCs consist of typical UV 
signatures, mainly being UVB induced CPD substitutions.190, 199, 200, 270 Previous studies have 
also demonstrated that SCCs could be separated into genetically distinct subpopulations 
related to the grade of differentiation, showing that SCCs with higher grade of differentiation 
possessed fewer genomic aberrations compared to moderately and poorly differentiated 
tumors.200, 269, 271 In recent genomic analyses of SCCs only a few real drivers of tumor genesis 
were identified and these were to a large proportion found in tumor-suppressor genes, such as 
p53, CDKN2A, and in NOTCH receptors.200, 272 CDKN2A is a cell cycle inhibitor and also 
important in epithelial transformation. NOTCH signaling is important in keratinocyte 
differentiation and can also be repressed by β-HPV infection.217 The frequency of activating 
mutations in RAS genes (H and K) are higher in SCCs arising in patients receiving the BRAF 
inhibitor vemurafenib200 compared to sporadic SCCs.268, 272 Mutations in KNSTRN have also 
been discovered in SCCs273 as well as in metastases from SCCs.274 KNSTRN encodes 
kinetochore protein, which is important for chromosome segregation and thereby a marker of 
aneuploidy. Activating mutations in TERT, which encodes telomerase, have been discovered 
to not only predispose carriers to melanoma but also in SCC and BCC.275, 276  
Genomic analyses of sporadic BCC have recently shown strong heterogeneity with abundant 
mutations, of which 75% were of UV-signature-types. Interestingly, mutations affecting the 
tumor-suppressor gene PTCH1, were the only tumor-driving mutations, confirming the 
central role of PTCH1 in BCC tumor genesis.277 A subgroup of sporadic BCCs has been 
found to carry activating SMO mutations, thereby bypassing PTCH in the hedgehog signaling 
cascade.84, 278 Oncogenic β-HPV types (5 and 8) have also been detected in BCC from 
OTRs.279 Whether BCCs from OTRs exhibit differing genomic changes is still unclear. 
Interestingly, one of the most prevalent completely benign skin tumors in the aged 
population, seborrheic keratoses, have been found to harbor a number of oncogenic mutations 
in several cancer genes, e.g. EGFR, FGFR2, PIK3R1, HRAS, KRAS, and NRAS. Almost 
50% of all cases revealed the presence of two oncogenic mutations in different genes, which 
obviously do not have a significant role in development or behavior of seborrheic 
keratoses.280 The authors concluded that lack of genetic instability and the absence of 
alterations in tumor-suppressor genes probably prevent seborrheic keratosis from malignant 
progression. An alternative explanation could be that seborrheic keratoses are a histologically 
heterogeneous group of keratinocytic tumors, a fact that may have influenced the finding of 
genetic diversity.  
Somatic mutations in melanoma (see chapter 1.2.3.3.) 
 38 
1.4  THERAPY AND PREVENTION 
1.4.1 Tumor destructive therapy  
Complete excision is the gold standard for all invasive skin cancer types; it is also the best 
prerequisite for accurate histological evaluation including resection margins. However, in 
OTRs with often many KCs and precursors the approach has to be more pragmatic, as not all 
lesions can be formally excised. The therapeutic arsenal of the surgical as well as topical 
treatment spectrum is broad; for example can destructive treatment alternatives be combined 
with photo-dynamic-therapy and CO2-laser. Treatment with chemotherapeutic 5-fluorouracil 
chemowraps for larger areas of diffuse actinic damage (i.e. field cancerization) has been 
proven very effective.281  
Imiquimod is a topical immune modulatory agent and used for a broad spectrum of 
superficial malignancies and precursors, including field cancerization.67 It was recently 
shown to also inhibit the hedgehog-signaling pathway, important in the etiology of BCC.282 
Vismodegib is a systemic targeted treatment against BCC and also inhibits the hedgehog 
pathway; and it is only indicated in patients with widespread and inoperable tumors. In 
OTRs, treatment with X-rays should be restricted to patients with inoperable tumors or in 
patients unable to tolerate surgical excision222, 283, because of lack of margin control and the 
tendency of OTRs to develop multiple adjacent tumors. 
 
1.4.2 Tumor prevention 
Acquiring cautious sun behavior after transplantation is highly recommended and patients 
receive information already before or shortly after transplantation, but this is not enough in 
fair-skinned OTRs.206 Publicly subsidized sun protection ointments for fair-skinned and 
especially for pediatric OTRs should be advocated, because of their evidence based effect on 
the prevention of mainly SCCs and AKs.284-286 Interestingly, exogenous DNA repair enzyme 
formulas might present a novel way to supplement intrinsic repair mechanisms and could be 
combined with sun protection or after-sun ointments.287  
In patients with moderate to severe tumor burden, specifically SCCs including precursors, 
and with stable organ function, secondary systemic chemoprevention with the retinoid 
acitretin can be considered.222 Systemic intake of capecitabine, a prodrug of 5-fluorouracil, 
has also shown to prevent development of SCCs and precursor lesions in OTRs.288 The 
efficacy of tumor prophylaxis by monthly subcutaneous injection of a synthetic α-
melanocytic stimulating hormone, afamelanotide CUV1647, has been proposed and tested in 
OTRs, but this treatment is so far not established.289 As mentioned previously (chapter 1.3.3), 
new vaccine formulations for the prevention of warts in children but consequently also of 
SCCs in OTRs, are under evaluation.225-227 
The reduction of immunosuppression and the switch to mTOR inhibitors, not only after a 
high-risk posttransplantation SCC, but also after other invasive skin tumors, e.g. melanoma, 
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invasive adnexal carcinomas, KS, MCC, is nowadays advocated.21, 163-165 If skin cancer 
burden is unacceptable and advanced, the cessation of immunosuppression (mainly in kidney 
OTRs) can be considered as a “last way out”, after which gradual deceleration of skin tumors 
usually takes place within 1 – 2 years.78, 156, 290 
For a subgroup of patients, tumor multiplicity can lead to severe impairment of quality-of-life 
and to adequately meet these patients needs, special clinics for transplant recipients at 
dermatology departments in larger centers have been built up throughout Europe, North 
America, Australia and New Zealand during the last 10 – 20 years.6, 290-292 Patient information 
material is extensive and since 2013 also available in Sweden.293  
The SCOPE Network, Skin Cancer in Organ Transplant Patients Europe, and the ITSCC 
Network, International Transplantation Skin cancer Collaboration, are interdisciplinary 
networks of dermatologists, transplant physicians, dermatopathologists, patient support 
groups and basic researchers brought together to meet the increasing need for qualified 
dermatological aftercare in this group of patients. Latest research is continuously 
exchanged during annual meetings and in collaborations.294, 295  
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2 AIMS 
The overall aim of this thesis is to improve the understanding of the greatly increased skin 
cancer incidence in organ transplant recipients (OTRs), and to discuss differences in possible 
underlying etiological factors, by focusing on histopathological and epidemiological aspects 
concerning three tumor types, i.e. SCC, BCC, and melanoma.  
The specific aims for each study were the following:  
Study 1: To test the hypothesis that the composition and the density of the peritumoral 
inflammatory infiltrate of cutaneous squamous cell carcinomas (SCCs) is influenced by the 
state of immunosuppression in OTRs and differs from SCCs in non-transplanted controls. In 
addition, the aim was to understand if systematic and computer-supported counting and 
measurement of different immune cell types in SCCs could help in testing this hypothesis. 
 
Study 2: To assess the level of relative risk of all cancer in Swedish OTRs, transplanted 1970 
– 2008, in comparison to the general population, and by type of transplanted organ, tumor 
site, and over time. A further aim was to study in detail the relative risk of different types of 
skin cancer and specifically risk of subsequent SCC. 
 
Study 3: To analyze clinical and histopathological characteristics of all posttransplantation 
melanomas, identified in Study 2, and to estimate melanoma-specific mortality among OTRs 
compared to melanomas in the general population.  
 
Study 4: To investigate the relative risk of BCC in OTRs, transplanted 2004 – 2011, 
compared to the general population by evaluating data from the Swedish BCC Register, 
established in 2004, and to compare BCC with SCC incidence. 
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3 SUBJECTS AND METHODS 
3.1 HISTOPATHOLOGY: STUDY 1 
3.1.1 Patients and SCCs 
Seven SCCs from OTRs who had been diagnosed with a total of at least five SCCs, dating 
from 1993 – 1997, were chosen from a collection of previously assessed SCCs.73 Fourteen 
SCCs from non-transplanted patients (controls), dating from 2003 – 2006 and retrieved from 
the archive of the Department of Pathology and Cytology, Karolinska University 
Laboratories in Huddinge, served as control tumors. By linkage with the Swedish Cancer 
Register it was ascertained that controls had not been diagnosed with previous SCCs or any 
other malignancy up to 2006 (see also chapter 3.2.1.3). All tumor slides were reassessed, 
distinguishing between in-situ and invasive forms as well as evaluating the grade of 
differentiation.69, 267 
3.1.2 Immunohistochemistry and special staining 
Immunohistochemistry is a multi-step technique for the detection and visualization of specific 
antigens, i.e. proteins, in tissue sections by using specific antibodies binding to the antigen 
and then binding of a secondary antibody to the first. Newly prepared tumor sections were 
immunostained by the peroxidase-anti-peroxidase method. Briefly, formalin-fixed and 
paraffin-embedded 4 µm sections from completely excised SCCs were deparaffinized and 
rehydrated, endogenous peroxidase was blocked, followed by overnight buffering. The order 
of the process was: Firstly, incubation with the primary antibody, secondly, incubation with 
an appropriate biotinylated “secondary antibody”, and thirdly, the adding of streptavidin 
peroxidase. The successful binding reaction was visualized with hydrogen peroxide as a 
substrate, diaminobenzidine chromogen, producing an insoluble brown color at the site of the 
antigen. Counterstaining with Mayer hematoxylin gave a clear blue color to the nuclei. The 
whole process was run automatically in the Dako REAL Detection System, Tech Mate TM 
500 PLUS (Dako, Denmark) according to the manufacturer’s recommendations.  
Tissue mast cells were stained with Astra Blue (Merck, UK).296 The method was tested on 
mast cell enriched tissue, i.e. a neurofibroma, and was initially also compared to alcian blue 
pH 2.5 and Toluidine blue. All staining methods were well established and standardized in 
routine laboratory practice at the Karolinska University Laboratories, Department of 
Pathology and Cytology, Huddinge.  
Table 8 outlines the staining pattern of the used immunohistochemical antibodies. 
3.1.3 Scanning of slides, measurements and cell enumeration process 
All tumor slides were scanned with the Mirax scanner (Carl Zeiss, Germany). Image viewing 
and analysis of the digital pictures was performed on a 30’’ monitor (Apple, USA). For area 
and circle measurements, and marking of “events”, i.e. counting of positively stained cells, a 
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commercially available interactive measurement module, Axio Vision version 4.6.3 (Carl 
Zeiss, Germany) was applied.  
Table 8. Inflammatory cell types with immunohistochemical staining pattern 
and criteria of “positive” cells 
 
Antibody CD3, 8, 20 CD4 CD56 CD138 
Cell type T-cells (CD3)  
Cytotoxic T-cells (CD8) 
B-cells (CD20) 
Helper T-cells, monocytes, 
macrophages, dendritic 
cells 
Natural killer cells Plasma cells 
Staining 
pattern 
Intense membranous, 
round cells 
Intensely stained cells in 
clusters. Difficult to count, 
so CD8 counts were 
subtracted from CD3 
counts, the remaining 
assumed to represent 
CD4+ cells. 
Membranous and 
cytoplasmic 
Cytoplasmic 
staining, round to 
oval nucleus with 
adjacent pale zone 
(Golgi) 
Lineage 
overlap 
CD8 can also be 
expressed by a subset 
of T-cells (gamma-
delta) and NK cells. 
Staining was less intense 
on monocytes, 
macrophages and 
dendritic cells 
Activated T-cells 
stain less intense 
NA 
 
 
CD14 CD1a CD68 Astra Blue 
Cell type Monocytes Langerhans’ cells Macrophages Mast cells 
Staining 
pattern 
Intense membranous 
and cytoplasmic, cells 
varied in size and 
shape some with 
dendrites. 
Intense membranous, cells 
varied in size and shape, 
often with dendrites. 
Intense cytoplasmic 
granules, sparsely 
membranous, cells 
were irregularly 
shaped.  
Abundant blue-
turquoise stained 
cytoplasm with dark 
purple nucleus, cells 
were large round to 
oval. 
Lineage 
overlap 
Intense staining on 
monocytes, 
macrophages and 
Langerhans’ cells, 
staining was less 
intense on neutrophils 
and B-cells 
NA Stains also some 
monocytes, NK 
cells, neutrophils 
and basophils 
NA 
NA denotes not applicable 
 
3.1.4 Study design 
The intention was to systematically investigate the quantity and type of the inflammatory 
cells in the microenvironment of in situ SCCs and infiltrative SCCs from OTRs in 
comparison to SCCs from immunocompetent controls. We chose to analyze one SCC from 
OTRs with at least five SCCs altogether, and compared them to SCCs from controls with 
only one SCC. The intention was to achieve the utmost polarization of OTRs with high tumor 
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burden versus controls with low burden. A few in situ tumors were also included in order to 
investigate differences in cell types in evolving compared to established/infiltrative tumors.  
Different methods of counting were initially discussed, including manual counting with the 
use of an optical grid in one eyepiece. This is tedious and difficult, and also less feasible for 
group discussion. Another option is estimating the proportion of positive cells by rating 
percentages semi-quantitatively. This method is less accurate but less time consuming. 
Further, we discussed how and where in the tumor vicinity inflammatory cells should be 
evaluated. Since inflammation appears mainly in a bandlike or patchy fashion adjacent to the 
infiltrative margin (infiltrative front) and is scarce within the SCCs, due to tumors often being 
solid and keratinized, we decided to count cells within different areas of the peritumoral zone.  
After the purchase of a digital slide scanner by the department of pathology and cytology, the 
production of high quality and high-resolution digital micro images was possible. With the 
aid of an interactive software program, secure, transparent and standardized tumor 
measurements, circle measurements as well as cell counting of cells, in addition to 
comprehensible documentation, could be realized.  
The method of computer-supported counting was at the time of the study (2007 – 2008) novel 
and similar studies on SCC had not used this approach.239, 242, 243 Because some tumors were 
quite large, not all cells in the peritumoral zone could be counted. Therefore a representative 
counting method of a large enough sample size of the peritumoral space was defined after 
statistical consultation and consideration of the following issues, outlined in Table 9. 
Table 9. Criteria with respect to the cell counting method 
1 Cell counting area had to be proportionate to tumor size, in order to achieve comparability, but also in 
order to calculate and compare cell densities (cells/mm2 tumor area) in the 2 sets of tumors 
2 The cell counting areas had to be equally sized, in order not to be biased by patchy infiltrates’ size 
3 Four equally sized cell counting areas were considered to be representative. Counting in fewer areas 
would have risked missing marked cells. Circular counting areas were chosen as a suitable format  
4 Each circle had to touch some of the tumor epithelium, in order to be certain of the infiltrates’ tumor 
proximity 
5 Circle placement was initiated on CD3 stained slides, because T-cells were in the majority and also 
because in markers with sparse positivity most cells were still located in and near the circles 
6 The aim was to place circles similarly throughout all markers (if infiltrates were mainly patchy placing 
circles in non-inflammatory areas was avoided) 
7 Creases and tissue rifts were avoided when placing circles (obvious intravascular cells were not 
counted) 
 
Adherence to these considerations led to the stepwise data acquisition process, outlined in 
Table 10.  
Table 10. Data acquisition process 
1 Measurement of tumor section area in mm2 
2 Division of 10% of the tumor section area into 4 equally sized circles 
3 Symmetrical placement of 2 circles on each lateral margin and 2 circles along the deep margin 
4 Counting of positive cells in the 4 circles, according to criteria in Table 8 
5 The sum of this count was used to calculate the percentages of the individual cell types in each SCC 
(total cell count in each tumor being 100%)  
6 Calculation of cell densities in each tumor: total cell count in tumor X divided by tumor section area 
tumor X = cells/mm2 
7 Statistical analysis was performed by ranking cell percentages of each cell type (Mann-Whitney U-test) 
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Figure 4 shows the author during the data acquisition process. 
 
3.1.5  Statistical analyses 
To test the hypothesis: “There are differences in the percentage distributions of subsets of 
inflammatory cell types and in cell densities in the peritumoral infiltrates of SCCs from OTRs 
compared to controls” against the null hypothesis, the non-parametric ranking test Mann–
Whitney U–test, also referred to as Wilcoxon rank sum test, was applied.297 This test is 
suitable for small data sets comprising values for which normal distribution is not expected 
and is more resistant to outliers. Instead of using the actual percentage values, these are sorted 
in ascending order of magnitude. The assigned rank numbers of the percentages of the 
different cell types as well as the cellular densities in each tumor were added up, separately 
for each group, OTRs and controls. Since the size of the OTR group was smaller, its sum 
determined the p-value.297 All analyses were performed using the SPSS software (former 
SPSS, Chicago, USA). 
 
3.2 EPIDEMIOLOGY: STUDIES 2, 3 AND 4 
3.2.1 The Swedish Personal Identity Number, Swedish registers, diagnosis codes, 
and OTR cohorts 
Studies 2, 3, and 4 were made possible owing to more than 50 years nationwide collection of 
high quality data in different health care registers in Sweden. 
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3.2.1.1 The Swedish Personal Identification Number (PIN) 
Each resident is assigned a unique PIN at birth or from date of permanent residency by the 
National Tax Board. The first 8 digits correspond to the date of birth; a 3-digit registration 
number (000-999) follows, in males always odd and in females even, the last digit is a check 
number.298 The PIN is essential to cross-link data from patient charts to national health care 
registers and thereby collect information from several sources and over time. PINs are 
sometimes changed, most commonly due to false registration of date of birth or gender. Also, 
PINs can be reused to immigrants. This is due to shortage of certain PIN combinations.111, 298  
In Studies 2, 3 and 4 the PINs from OTRs were linked to the Swedish National Patient 
Register (2, 4), to the Swedish Cancer Register (2, 4), to the Swedish Melanoma Register (3), 
to the Swedish Cause of Death Registry (2, 3, 4), and to the BCC Register (4).  
3.2.1.2 The Swedish National Patient Register (SNPR) 
The National Board of Health and Welfare began collecting data on individual hospital 
discharges and surgical procedures in the SNPR in 1964. All four national transplant centers 
(Stockholm, Uppsala, Göteborg, Malmö) were covered since 1970. Information collected is 
patient data (PIN, gender, age, place of residence), geographical data (county council, 
hospital/clinic, department), administrative data (e.g. date of admission and discharge, acute 
or planned admission), and medical data (e.g. main and secondary diagnosis, surgical 
procedure codes).299, 300 The overall completeness of the data is regularly monitored. Missing 
data have been reported to be less than 2% and coding of surgical procedures revealed high 
accuracy.301 In Studies 2 and 4, OTR cohorts were established through the SNPR. 
Diseases are recorded according to the current revision of the WHO International 
Classification of Diseases (ICD). During the period of investigation, 1970 – 2008 (Study 2) 
and 2004 – 2011 (Study 4), OTRs of any solid organ (kidney, liver, heart, lung, pancreas and 
small intestine) were identified by surgical procedure codes. Current procedure codes are 
based on the Swedish Classification of surgical and medical procedures, issued by the 
National Board of Health and Welfare.302 
Coding of the underlying diagnosis/es leading to transplantation (Study 2) were based on 
ICD8 – 10 (1970 – 1986 ICD8, 1987 – 1996 ICD9, and from 1997 ICD10).301 
3.2.1.3 The Swedish Cancer Register (SCR) 
Since 1958 the National Board of Health and Welfare collects nationwide information on 
cancer incidence in Sweden in the SCR.303 Initially the six regional cancer registers gather 
and validate incoming reports on cancer occurrence. The reporting of every primary cancer 
case by both the diagnosing physicians and pathologists is mandatory by law, resulting in 
near complete registration.304 All malignancies and precancerous lesions, i.e. severe 
atypia/dysplasia, epithelial and melanocytic, cancer in situ, as well as some benign tumors 
(mainly of the central nervous, genito-urinary and endocrine system) are reported.  
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Three types of information are registered: patient data (e.g. PIN, place of residence), medical 
data (e.g. anatomical tumor site, histological type, basis of diagnosis, i.e. by morphologic 
analysis, radiology or autopsy, and date of diagnosis), and lastly, follow-up data (e.g. date of 
death, cause of death, date of migration).303  
Tumor site and histopathology (morphology) are recorded according to the current ICD 
classification, since 2005 ICD-O/3 – ICD10 system of topography and morphology. For 
historical comparability, codes are translated to all recent classifications, i.e. ICD-O/2 (1993 – 
2004), ICD9 (1987 – 1992), and ICD7 (1970 – 1986). During the periods of investigation, 
1970 – 2008 and 2004 – 2011, coding of the histopathological tumor type was based on 
WHO C24.1/hist (1970 – 1992), ICD-O/2 (1993 – 2004), ICD-O/3 (since 2005).305  
For example, the current morphology code of SCC is M80703 (ICD-O/3 and ICD-O/2); 
historical codes are 146 (C24.1) and 191 (ICD7). Invasive melanoma is currently coded 
M87203 and historical codes are 176 and 190. The current code of KS is M91403 and 
historical codes are 566 and 191. The current code of MCC is M82473 and historical codes 
are 446 and 191. The current code of adnexal skin carcinomas not otherwise specified is 
M83903 and historical codes are 046 and 191.  
3.2.1.4 The Swedish Basal Cell Carcinoma Register (BCC Register) 
The BCC Register was established 2003 and is part of the SCR.85 Registration has been 
nationwide since 2004. The diagnosing pathologist (but not the clinician) must report all 
newly diagnosed BCCs to the BCC Register, and registration is triggered by ICD-O/3 
morphology codes. Information registered is the PIN, anatomical tumor site, and histological 
type. The histological classification is based on criteria of Sabbatsberg/Glas (Table 2), by 
estimating the putative biological aggressiveness of the tumor.90 To minimize repeated 
registration, BCCs that already have been reported, e.g. by a former punch biopsy, are coded 
accordingly and are excluded from renewed registration, and so are also local recurrences. 
Data from the BCC Register were analyzed in Study 4. 
3.2.1.5 The Swedish Melanoma Register (SMR) 
The SMR is a quality register and was founded in 2003 by the Swedish Melanoma Study 
Group.132 The SMR lies under the supervision of the regional cancer center of Östergötland. 
Since 1990, clinical data (e.g. date of diagnosis, tumor site) and histopathological parameters 
(e.g. millimeter thickness, Clark level, ulceration, tumor type) as well as clinical stage of 
invasive melanomas have been assembled prospectively, according to the guidelines of the 
American Joint Committee on Cancer (AJCC) 2001130, and from 2011 according to the AJCC 
guidelines of 2009.131 The registration has been nationwide since 1996 and the completeness 
is approximately 97%.132 The SMR is regularly updated against the SCR and the National 
Cause-of-Death Register. Data from the SMR was analyzed in Study 3. 
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3.2.1.6 The Swedish Cause of Death Register (SCDR)  
In Sweden, the registration of causes of death according to international standards set up by 
the WHO started in 1951.306 The National Board of Health and Welfare founded the SCDR. 
Information of all deceased residents in Sweden is annually collected from death certificates, 
e.g. PIN, date of death, and cause of death. In 2013, the death certificate was missing in 1,1% 
of all deaths.307  
The cause-of-death diagnosis is defined as the principle underlying condition that started a 
chain of events leading to the individuals’ death; it is currently coded according to ICD10. 
The quality of the cause-of-death registration may vary, mainly due to variations in the 
accuracy of the attending physicians’ report but also due to changes in autopsy frequency. In 
a study on the quality of cause-of-death registration, the underlying diagnosis due to a 
malignant neoplasm had highest accuracy, 90 – 98%.308  
 
3.2.2 Study design 
3.2.2.1 Study 2 
This study was initially planned as a follow-up of a previous population-based study on 
cancer risk in Swedish OTRs transplanted 1970 – 1997.11 The new OTR cohort from 1970 – 
2008 was nearly double in size and risk analyses were stratified by organ type and over time 
since transplantation. Relative risk of all invasive cancer types according to site was analyzed 
with a focus on skin cancer, specifically SCC multiplicity. Also risk of melanoma and rare 
skin cancer types such as KS, MCC, and adnexal skin carcinomas were assessed, as well as 
cancers in skin adjacent mucous membranes (oral and genital). OTRs with a history of cancer 
prior to transplantation and OTRs diagnosed with cancer within 30 days of transplantation 
were excluded. Follow-up started 30 days posttransplantation and extended until death, 
emigration or end of the study, which was on December 31, 2008. 
3.2.2.2 Study 3 
The intention was a descriptive study of clinical and histopathological characteristics of 
melanoma in OTRs. In Study 2, 52 melanomas in 51 OTRs were identified and risk of 
melanoma was 2.2-fold increased compared to the general population, whereas in the 
previous study by Adami et al.11, and Lindelöf et al.55 risk of melanoma had not been 
significantly increased.  
All melanomas were reassessed on hematoxylin-eosin stained slides, in order to achieve 
uniform pathological grading according to the current and former classification of the 
AJCC.130, 131 The association of a preexisting melanocytic nevus, either dysplastic/atypical 
(DN) or common/ordinary, was assessed.267 The pattern of tumor-infiltrating lymphocytes 
(TILs) was semi-quantitatively graded as absent, sparse or abundant.123 
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Melanoma characteristics in OTRs, including follow-up data on clinical stage and mortality, 
were compared with all population melanomas from the SMR between 1990 and 2007 from a 
previously established cohort.309 Follow-up of OTRs and population ended December 31, 
2012.  
 
3.2.2.3 Study 4  
The intention was to study relative risk of BCC in OTRs, transplanted 2004 – 2011, in 
comparison to the general population (SIR). Analyses were stratified according to gender, age 
at transplantation, organ type, and time since transplantation.  
In order to compare BCC with SCC incidence in OTRs, the SCC to BCC ratio was 
calculated. BCC types and anatomical localization in OTRs were compared to BCCs in the 
general population. Follow-up started 30 days from date of transplantation and ended at death 
or end of the study, which was on December 31, 2011.  
 
3.2.3 Statistical analyses 
3.2.3.1 Standardized incidence ratios (SIR) (Studies 2 and 4) 
To study cancer incidence and relative risk (SIR) of cancer in OTRs the rate in OTRs was 
estimated, i.e. the observed number of cancer cases divided by the expected number in the 
general population for each particular malignancy.297 The expected numbers of cancers 
depend on age, gender and calendar period in the general population. They were calculated 
by multiplying the age-, gender-, and calendar period- specific follow-up time (person-time) 
in the OTR cohort with the corresponding incidence in the general population. After 
estimating the ratio between the observed and the expected number of cancers, the Poisson 
distribution was used to calculate relative risk with its 95% confidence intervals (CI).310, 297  
A result can be expressed in the following manner: SIR 2.1; 95% CI: 1.9-2.4; in this example 
the relative risk is 2.1-fold increased compared to the general population and considered 
significant as it lies within the upper and lower CI limits, indicating a 95% confidence that 
the true risk lies in between these limits.  
3.2.3.2 Incidence rate ratios (IRR) (Studies 2 and 4) 
In Study 2, the relative risk analyses of cancer incidence (all cancer excluding SCC, of a first 
SCC and of additional SCCs) within the total cohort of OTRs were modeled in a standard 
linear regression model using the Poisson regression method to control for confounding 
effects of more than one variable297, e.g. gender, age at transplantation, organ type, period of 
transplantation, time since transplantation as well as indication of transplantation. All 
variables were treated as categorical exposure variables and were time-dependent; thereby 
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patients were allowed to move between categories with time. IRR were estimated for each 
non-baseline group compared to the baseline, for example male (for gender) and kidney (for 
transplanted organ) were set as the reference. Tests for linear trends over calendar time for 
all cancer excluding SCC and for SCC were performed, 95% CI were calculated. A similar 
risk analysis was performed for estimating risk of additional SCCs, i.e. risk according to time 
since most recent SCC and according to number of previous SCCs.  
In Study 4, the relative risk analyses of BCC incidence within the total cohort of OTRs were 
estimated using negative binomial regression as an alternative to Poisson regression to 
account for overdispersion due to multiple events within individuals.297 Time since organ 
transplantation was the underlying time scale with the logarithm of time at risk as an offset in 
the model to account for different length of follow-up. The model included gender, age at 
transplantation, organ type, and time since transplantation. Time since transplantation was 
considered as a time-dependent variable, allowing individuals to move between categories 
with time. IRR were estimated for each non-baseline group compared to the baseline, for 
example male (for gender) and kidney (for transplanted organ) were set as the reference. In a 
separate model IRR were estimated for groups of cancer diagnoses before transplantation 
(SCC, melanoma, and non-skin cancer), also including age, gender, and time since 
transplantation. The proportional hazard assumption was evaluated by likelihood ratio tests of 
interaction terms between each covariate and the underlying time scale. There was no 
evidence of non-proportional hazards for the models.  
3.2.3.3 Logistic regression, odds ratios (OR) (Study 3)  
This is a method for determining the relationship between one or several independent 
exposure variables and a dichotomous dependent variable, e.g. transplanted yes/no. The 
exposure variables of the melanoma characteristics, for example tumor thickness, were 
treated as categorical variables and grouped according to the AJCC classification.130 To 
assess the relationship between the exposure variables and the dependent variable, the odds 
ratio (OR) was estimated. The OR can also be defined as a measure of probability (i.e. the 
ratio of the odds of an event occurring in one group to the odds of it occurring in another 
group). It is a ratio of odds and differs from relative risk estimates, which is a ratio of risk. 
ORs were estimated for each non-baseline group compared to the baseline, e.g. Clark level 
III-V versus Clark II. A multinomial logistic regression model was used that also included 
gender, age at diagnosis, health care region, and period of diagnosis (confounders), to adjust 
for any potential effect of these variables.297 ORs were expressed with 95% CI. Missing data 
for Clark level, ulceration and clinical stage were omitted.  
3.2.3.4 Cox proportional hazard regression (Study 3) 
The Cox proportional hazard method was used to analyze the relative risk effect, hazard 
ratios (HR), between groups using time to event as outcome, i.e. melanoma-specific death.111, 
297 This was done under the assumption of proportional hazards, i.e. that the ratio of the 
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hazards comparing the two groups remains constant over the study period. This was tested for 
overall and melanoma-specific death using a time-dependent test variable.297  
The Cox regression analyses were adjusted for confounders that are not intermediate steps in 
the causal pathway to melanoma death, such as age at diagnosis, gender, period of diagnosis 
and health care region. The impact of prognostic factors was presented as HRs with 95% CIs 
and associations were considered significant at a p-value of <0.05. Also, stratification for 
tumor thickness ≤/>1.0 mm and ≤/>2.0 mm was done. Missing data were treated as separate 
categories and the main effects of “missing” were estimated before adjustments for 
confounding. 
3.2.3.5 Cumulative incidence (Studies 2, 3, and 4) 
The cumulative incidence is the risk of a disease to occur, i.e. the probability to occur within 
a specific time period. It is estimated by the number of new cases divided by the number of 
persons at risk, i.e. those initially disease-free, all within a specified time period297, and 
expressed as x% after x years. 
In Study 2 cumulative incidences of first cancer, excluding SCC and of first SCC were 
stratified by organ type (kidney, heart and/or lung and liver). In Study 4 cumulative 
incidences of first BCC were also stratified by organ type. Further, cumulative incidences of 
additional SCCs and BCCs in relation to previous number of tumors were similarly plotted. 
All cumulative incidence analyses accounted for the competing risk of death. 
In Study 3 cumulative incidence of melanoma-specific and other-cause of death were 
estimated using the Gray’s Test for Equality of Cumulative Incidence Functions, treating 
other causes of death as a competing risk.311 This approach is similar to an inverted Kaplan-
Meier survival analysis with the exception that cumulative incidences are not censored for 
death of any other-cause than melanoma. For example, the risk of melanoma-specific death 
5 years after diagnosis was 25% in OTRs compared to 10% in population melanomas.  
 
Analyses in Study 2 and 3 were performed using the SAS software package, Version 9.2 
(SAS institute, North Carolina, America). For plotting of cumulative incidences the 
CUMINCID macro within the SAS package was used in Study 2. In Study 3 the macro 
‘%CIF’(available at http://support.sas.com/resources/papers/proceedings12/344-2012.pdf) 
was copied into the program code. In Study 4 all analyses were performed with SAS 
statistical Analysis Software, version 9.4 as well as with STATA 13.0.  
3.3 ETHICS 
The Regional Ethical Review Board in Stockholm gave ethical approval: Study 1: 2006/577-
31/1 and 97-006 with supplement 00-062. Studies 2, 3, and 4: 2007/1485-31/4 and 2008/452-
3.  
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4 RESULTS 
This section presents the study-specific results from the articles and manuscripts. 
4.1 STUDY 1 
Altogether nearly 100,000 cells were defined and counted. A significant difference in the 
percentage distribution of subsets of inflammatory cells in the peritumoral infiltrate of SCCs 
from OTRs in comparison to SCCs from immunocompetent controls was noted for T-cells 
(CD3), plasma cells (CD138), and monocytes (CD14). T-cells (CD3) were the dominating 
cell type in the peritumoral infiltrates, the median percentage was 57% (range, 35 – 78) in 
OTRs and 68% (48 – 80) in controls, p = 0.036. The median percentages of plasma cells 
(CD138) was 2% (0.7 – 7) in OTRs compared to 0.2% (0 – 1.2%) in controls, p = 0.001, and 
of monocytes (CD14) 3.2% (1.1 – 5.6) in OTRs and 9.3% (2.2 – 17.2) in controls. 
Percentages of B-cells (CD20) were increased only at the lateral tumor margins but not in 
total: 12.2% (3 – 38%) in OTRs versus 4.1% (0 – 33%) in controls, p = 0.036. When 
comparing median cell densities in SCCs from OTRs with controls, no differences were 
noted; in OTRs median density was 328 cells/mm2 tumor section area (range, 160 – 523) and 
in controls 323 cells/ mm2 (121 – 814). Tumor area was compared in a similar fashion and no 
difference was noted (p = 0.20).  
 
 
Figure 5 shows the percentage distributions of SCCs from OTRs and immunocompetent 
controls in a histogram. 
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Figure 5. Percentage distributions of inflammatory cell types in  
OTRs versus controls 
 52 
4.2 STUDY 2 
Population-based relative risk of cancer in more than 10,000 OTRs who had been followed 
for more than 20 years with the longest individual follow-up time of 38 years (in total 93,432 
person-years) was estimated. Analyses showed distinct variations in cancer risk according to 
the organ type and to follow-up time. Altogether, 1,610 OTRs were diagnosed with 3,406 
malignancies; of these 668 patients developed 2,231 SCCs and 1,036 patients developed 
1,175 cancer types other than SCC.  
Risk of SCC outranked all other cancer risks and risk was highest among heart and/or lung 
OTRs (SIR 198), followed by kidney OTRs (SIR 121), and lowest in liver OTRs (SIR 32). 
During follow-up, risk of SCC tripled over 20 years irrespective of graft type. This was 
partly due to a small group of patients accumulating a large number of SCCs at an 
accelerating rate, for example, after a 5th SCC, the risk of developing yet another SCC 
within two years exceeded 80%. The risk for all other cancer types was 2 – 3 fold increased 
and remained stable during follow-up. 
 
 
In Figure 6 cumulative incidences of additional SCCs in all OTRs stratified by number of 
previous SCCs are shown. 
 
The skin cancer group included also 52 melanomas diagnosed in 51 patients (SIR 2.2, 95% 
CI 1.7 – 2.9). High relative risks were also observed of rare skin malignancies, i.e. 9 MCCs 
SIR 65 (30 – 124), 7 KSs SIR 39 (16 – 81), 22 adnexal carcinomas SIR 40 (25 – 61), and of 
cancer at mucosal skin-adjacent sites, i.e. 8 penis cancers, SIR 7.4 (2.2 – 15).  
Figure 6. Cumulative incidence of additional SCCs in all 
OTRs according to number of previous SCCs  
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The risk of kidney, liver and lung cancer were substantially increased among kidney, liver 
and lung OTRs, respectively.  
In Table 11 relative risks (SIR) are listed of the most common cancer types in OTRs. 
 
Table 11. Standardized incidence ratio (SIR) of most common cancer 
types in OTRs* by organ type 
Site Kidney Liver Heart and/or lung 
 Observed SIR 
95% CI 
Observed SIR 
95% CI 
Observed SIR 
95% CI 
SCC 1,846 121 
(116-127) 
51 32 
(24-42) 
244 198 
(174-224) 
NHL 84 4.8 
(3.8-5.9) 
24 
 
14 
(8.9-21) 
36 24 
(17-34) 
CIN III 75 3.0 
(2.4-3.8) 
NS NS 7 4.7 
(1.9-9.7) 
Kidney 70 6.2 
(4.8-7.9) 
NS NS NS NS 
Colon 62 2.3 
(1.8-2.9) 
NS NS NS NS 
Lung 55 1.7 
(1.3-2.2) 
NS NS 15 5.4 
(3.0-8.9) 
Melanoma 44 2.3 
(1.7-3.1) 
NS NS NS NS 
Liver 20 2.7 10 14 NS NS 
Stomach 17 1.8 NS NS 6 9.2 
(3.4-20) 
* OTRs with a history of cancer prior to the date of transplantation were excluded from the study cohort 
NS denotes not significant 
 
4.3 STUDY 3  
From the index cohort (Study 2) all 52 melanomas were retrieved and after histopathological 
reassessment 49 melanomas in 49 OTRs remained for further analyses. Two were relapses 
and one patient developed 2 melanomas, this patients’ follow-up time was censored at the 
date of the second melanoma.  
 
Results of Study 3 are listed in Table 12. 
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Table 12. Results of Study 3 
Descriptive 
comparisons 
 
71% OTRs with melanoma were males, n=35, and 84% were kidney OTRs, 
n=41; compared with 50% males and 50% females (n=22,496) in the 
population melanomas. 
In OTRs, the trunk was the dominating anatomical site: 51% males and 50% 
in females; compared with 61% males and 34% females in the population 
melanomas. 
In OTRs, melanomas were mainly pT1 (48%) and pT2 (22%); compared with  
pT1 (55%) and pT2 (20%) of the population melanomas. 
In OTRs, melanomas were mainly of SSM type (47%) compared with  
 61% of the population melanomas. 
Odds ratio 
(OR) 
In OTRs, melanomas were more advanced at diagnosis according to Clark 
level: III-V versus II OR 2.2 (but not according to tumor thickness), and also 
according to clinical stage: III-IV versus II and I OR 4.2 
Reassess-
ment of slides 
73% (n=36) of all melanomas in OTRs were histologically associated with a 
melanocytic nevus: 63% (n=31) DN. 
Most commonly associated with a melanocytic nevus was the 
lentiginous/nested subtype (9 out of 10 melanomas with DN, 90%) followed by 
the SSM subtype (18/23, 78%). 
Two posttransplantation melanomas exhibited a so-called abundant pattern of 
tumor-infiltrating lymphocytes (TILs), all others had a sparse or absent 
pattern. 
Hazard ratio 
(HR) 
Risk of melanoma-specific death was 3.0-fold increased among OTRs versus 
the population. 
Melanoma-specific death was 3.7-fold increased among tumors ≤ 2.0 mm, 
and 3.1-fold among tumors >2.0 mm, HR was 3.7-fold increased among 
tumors ≤ 1.0 mm, but this was not significant. 
All melanoma-specific deaths in OTRs occurred within 5 years from the 
diagnosis compared to 10% in the population and HR remained stable during 
these first 5 years (Figure 7). 
 
 
 
 
 
Figure 7. Cumulative incidence of melanoma-specific death in OTRs  
and in the general population 
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Figure 7 describes cumulative incidence of melanoma-specific death in OTRs and in the 
general population. 
 
 
Examples of microphotographs from reassessed melanomas are shown in Figures 8 and 9.  
   
Figures 8a (left) and b (right): Microphotographs of an ALM: 1.4 millimeter, pT2a with a 
preexisting common/ordinary nevus adjacent to the infiltrative component (right), no 
ulceration, no signs of inflammation (TILs). With permission from the late Dr. Mecius 
Simanaitis. 
The patient was a female kidney recipient, 64 years old at transplantation, transplanted due to 
nephrosclerosis. Fifteen years after transplantation she developed a lesion on the sole of the 
foot. She died one year after the diagnosis because of tuberculosis. No other skin cancers or 
non-skin cancers had been reported. 
 
   
Figures 9a (left) and b (right): Microphotographs of a SSM, 0.5 millimeter, with one mitosis 
(depicted in the rectangle in b), pT1b, no ulceration, sparse inflammation (TILs). With 
permission from the late Dr. Mecius Simanaitis. 
The patient was a female kidney and liver recipient, 40 years old at transplantation, and 
transplanted due to polycystic kidney disease. Twenty-five years after transplantation she 
developed a lesion on the arm. She died 5years after the diagnosis, because of a “malignant 
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tumor in the liver and metastases of a malignant tumor”. Hence, it was uncertain if death was 
melanoma related. Seven SCCs and several BCCs had also been reported in this patient.  
 
4.4 STUDY 4 
The study cohort of OTRs, transplanted 2004 – 2011, comprised 4,023 individuals; the 
majority were kidney recipients (59%). Median age at transplantation was 53 years and 
median follow-up time was 3.4 years. Altogether 175 OTRs developed 341 BCCs, 63% 
males and 37% in females, more than one BCC was contracted by 49% of OTRs. BCC 
characteristics were compared to 289,498 BCCs contracted by 177,177 individuals in the 
general population, 49% males and 51% females, more than one BCC was contracted by 39% 
of the population.  
Relative risk of BCC was 6.1-fold increased (SIR 6.1, 95% CI 5.4 – 6.9) and risk was highest 
in kidney OTRs (SIR 7.2, 6.3 – 8.3), followed by heart and/or lung OTRs (SIR 5.8, 4.0 – 8.2), 
and lowest in liver OTRs (SIR 2.6, 1.7 – 4.0).  
Table 13 outlines the relative risk (SIR and IRR) of BCC in OTRs. 
 
Table 13. Relative risk (SIR and IRR) of BCC in OTRs 2004 - 2011 
 SIR 
95% CI 
IRR 
95% CI 
Overall 6.1 (5.4 – 6.9) NA 
Gender 
Males 
Females 
 
6.3 (5.2 – 7.6) 
6.0 (5.1 – 7.0) 
 
1.0  
1.2 (0.7 – 2.0) 
Age at transplantation, y 
<45 
45-54 
55-64 
≥65 
 
5.3 (2.9 – 9.5) 
6.7 (4.9 – 9.0) 
7.2 (6.2 – 8.5) 
4.3 (3.3 – 5.5) 
 
0.1 (0.0 – 0.1) 
0.4 (0.2 – 0.9) 
1.0  
1.2 (0.6 – 2.4) 
Organ type 
Kidney 
Liver 
Heart and/or Lung 
Other 
 
7.2 (6.3 – 8.3) 
2.6 (1.7 – 4.0) 
5.8 (4.0 – 8.2) 
4.0 (1.5 – 10.7) 
 
1.0  
0.3 (0.1 – 0.6) 
0.8 (0.3 – 1.6) 
0.4 (0.1 – 1.5) 
Time since transplantation, y 
0–2 y 
3–5 y 
≥ 6 y 
 
5.8 (4.8 – 6.9) 
7.0 (5.9 – 8.3) 
3.3 (1.8 – 5.9) 
 
1.0  
2.2 (1.4 – 3.3) 
2.0 (1.0 – 4.0) 
Cancer prior transplantation 
No prior Melanoma 
Melanoma  
No prior SCC  
SCC 
No prior non-skin cancer 
Non-skin cancer 
 
 
NA 
 
1.0  
1.6 (0.4 – 6.3) 
1.0  
55.3 (16.3 – 188) 
1.0  
1.2 (0.5 – 2.8) 
SIR denotes standardized incidence ratio, IRR incidence rate ratio, NA not applicable 
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We also analyzed relative risk of a subsequent BCC after the diagnosis of a SCC prior to 
transplantation. Risk was 55-fold increased, while a melanoma or any non-skin cancer 
diagnosis prior to transplantation did not increase BCC risk, Table 13.  
The SCC to BCC ratio was 1: 1.7. BCCs developed earlier after transplantation compared to 
SCC, e.g. at five years posttransplantation the cumulative incidence of first BCC among 
kidney recipients was nearly 7%, compared to a cumulative incidence of first SCC of 0.4% 
reported in kidney OTRs in Study 2.  
The number of already diagnosed BCCs was associated with risk of developing an additional 
BCC. For example, among OTRs with a minimum of two previous BCCs, 38% developed 
another tumor within two years and among those with 3 or more BCCs, 84% developed 
another BCC within 2 years, Figure 10. 
 
 
In Figure 10 the cumulative incidences of additional BCCs in all OTRs stratified by number 
of previous BCCs are shown 
 
In OTRs the anatomical tumor sites were strongly associated with the head followed by the 
trunk in both females and males, indicating a preference for chronically and intermittently 
sun exposed sites analogous to the general population. 
  
Figure 10: Cumulative incidence of additional BCCs in OTRs according 
to number of previous BCCs 
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5 METHODOLOGICAL CONSIDERATIONS 
5.1 STUDY 1 
Archived tumor blocks were used in this study, why former processing methods and 
condition of storage of the tumor specimen and the paraffin blocks were out of our control. 
Also, we had no knowledge on whether all tumor material had been embedded. While 
different storage practices of paraffin blocks might have influenced staining features in 
immunohistochemistry, we believe that the risk is minimal, since we only used well-
established markers and methods from routine laboratory practice.  
Furthermore, we were aware of the fact that immunohistochemistry is not a totally specific 
method and had to accept some lineage overlap of markers (Table 8). Our laboratory at that 
time was not practicing double staining of markers and we could not do serial levels in order 
to follow certain cells and thereby detect “double” staining features.  
The choice of immunohistochemical markers was conservative, since more recent markers, 
for example for regulatory T-cells as well as for subtypes of dendritic cells, were not 
implemented in our laboratory and thus not used in this study.  
It was not possible to perform cell counting in a totally blinded fashion, since the author did 
all organizational work and thus held all information on tumor origin. However, the co-
authors did not have access to this information and so the process was at least partially 
blinded. Furthermore, the evaluation of cell counts was done after the counting process was 
completely finished. 
The sample size was small, but after statistical consultation considered sufficient. Also, 
although semi-quantitative rating of cell distributions would have made a larger sample size 
possible, the financial framework limited the sample size.  
On average SCCs from OTRs were smaller in size compared with SCCs from controls; this 
was surprising and could imply that we compared cellular infiltrates in evolving/early SCCs 
in OTRs with established/mature SCCs in controls. The difference in tumor size can have 
been an unintended result of the segregation of OTRs with many SCCs versus controls with 
only the index SCC, because it can be assumed that OTRs with many tumors were regularly 
monitored and therefore tumors were detected early and still small. In contrast to controls, 
who may have waited longer for medical consultation and therefore developed larger tumors. 
The study outcome might have been influenced by the differing tumor size in the two groups 
and an alternative study approach could have been to compare OTRs’ SCCs to controls with 
high tumor burden. However, that study design would have needed more cases, as the only 
segregating factor would have been immunosuppression or not. 
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5.2 STUDY 2 
In situ cancers were not included in this study, the only exception were cervical cancers CIN 
III. The reporting of in situ malignancies/pre-malignant lesions of any kind to the Cancer 
Register is variable, why coverage is uncertain. For example the diagnosis of a squamous cell 
carcinoma in situ is by definition true for Bowen’s disease but also applicable for actinic 
keratosis with severe dysplasia.  
Basal cell carcinomas are usually included in the group of skin cancer excluding melanoma 
(ICD7 191); relative risk of BCC could not be analyzed in this study because of incomplete 
registration during the study period.  
A further limitation of this retrospective register study was that we were unable to 
scrutinize over 10,000 patient records; we therefore lacked information about possible ex-
plantation and re-transplantation. Thus, minor misclassification of exposure, including 
follow-up time with and without immunosuppressive treatment, could have led to an 
underestimation of the excess risk actually entailed by immunosuppressive drugs, 
presumably mainly for kidney recipients.  
 
5.3 STUDY 3 
The small sample size of only 49 melanomas was a limitation of this study’s statistical 
analyses. In the Cox regression (HR) we adjusted for confounders, which are variables that 
are related to exposure and outcome without being an intermediate step in the causal pathway 
to melanoma-specific death (age at diagnosis, gender, health care region, and period of 
diagnosis), in order to compensate for some imbalances in the two cohorts by these factors. 
A potential confounder not included in the model was socioeconomic status, which to some 
extent has been compensated by adjustment for health care region, as this variable separates 
affluent urban areas from poorer suburban and rural areas. Also, the health care system in 
Sweden is tax-funded and open to everyone regardless of socioeconomic background, 
ensuring that patients were not selected for organ transplantation based on their financial 
situation. 
Comparison of OTRs’ melanomas with those of the general population was hampered by 
imbalances in gender and age distribution: for example 29% females versus 71% males in 
the OTR cohort compared with 50% females versus 50% males in the population, reflecting 
actual melanoma distributions in Sweden. Therefore, all population melanomas in the SMR 
were included (also cases with missing data).  
Reassessment of a sample of population melanomas (approximately 200 – 250) would have 
added to a more accurate description of the histopathological tumor details. Additionally, it 
would have made statistical comparisons (especially concerning the coexistence of a tumor 
adjacent melanocytic nevus and the examination of tumor infiltrating lymphocytes) 
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possible. However, reassessment also of population melanomas would have been too time 
consuming. 
 
5.4 STUDY 4 
Short follow-up time was the main limitation of this study, which was due to the lack of 
nationwide BCC data prior to 2004.  
There are some concerns on the quality and completeness of the data assembled in the BCC 
Register, which amount to possible limitations regarding both OTRs’ and population BCCs:  
• Double reporting is probably mainly due to repetitious registration of falsely coded 
BCCs in re-excisions and in relapses, often due to lack of clinical information.  
• Underreporting is probably mainly due to an in-born coverage deficit regarding BCCs 
that are treated on clinical suspicion only. 
• Guidelines for the classification and appropriate coding of BCCs have existed in 
Sweden since 2002. If followed, these should restrict overregistration, and prompt 
better classification (by use of correct codes). 
• Errors in coding of tumor type are probably frequent because many tumors are pre-
diagnosed by a punch biopsy, which is often not representative of the whole lesion.  
• Errors in coding of the anatomical location can also be expected. This is why 
presentations of the distribution of tumor types and anatomical sites probably have to 
be regarded with some degree of skepticism. 
So far no study has been published on the BCC Register’s quality and completeness. Very 
high quality, comparable to the Swedish Cancer Register will probably not be observed, but 
from clinical experience, the author speculates, that quality of BCC registration is at least 
moderate and although its many limitations, it should be emphasized that the Swedish BCC 
Register is unique as it is nationwide and population-based and therefore has to be regarded 
superior to data in other studies presented in this field so far. 
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6 DISCUSSION 
In the four studies of this thesis, important findings were made as follows: 
In Study 1, the composition of inflammatory immune cells in the peritumoral space differed 
between SCCs from OTRs compared to SCCs from immunocompetent controls, indicating an 
inflammatory imbalance. Also, cellular densities in SCCs from OTRs and controls were 
equal, indicating adequate cell recruitment into the peritumoral space. 
Few studies have analyzed the cellular composition of the peritumoral inflammatory 
infiltrate in SCCs from OTRs. In the present study, a reduction in proportions of cells 
expressing CD3, CD8, and CD14 (monocytes/macrophages) was noted.312 Others have 
described a reduction in the proportions of FOXP3 (regulatory T-cells, T-regs, but possibly 
also activated and/or memory T-cells), CD123 (plasmacytoid dendritic cells, DCs), and also 
CD11c (myeloid DCs).313, 314 In our study, the proportion of CD138 (plasma cells) was 
higher in OTR-SCC compared to SCCs from immunocompetent patients.312  
The described cellular imbalances give support to a possible hypothesis for SCC 
progression in OTRs: lower T-cell proportions with reduction of CD8 cytotoxic T-cells, and 
increase of CD4 helper T-cells (supported by a higher CD4 to CD8 ratio found in our study, 
although not significant). Further, lower counts of APCs, i.e. subsets of DCs314, and 
therefore a reduced ability to present tumor-antigen to CD4 helper T-cells can imply a shift 
towards a type 2 dominated tumor microenvironment (Th2). How the reported reduction of 
T-regs (measured by expression of FOXP3) really converts to a reduced proportion of T-reg 
function is still unclear.228  
 
Figure 11, illustrates the hypothesis of the imbalance in the composition of the cellular 
microenvironment in SCCs in OTRs. 
? 
Figure 11. Hypothesis of an imbalance in the cellular 
tumor microenvironment in SCC in OTRs 
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In a recent study of expression of different sets of genes relating to type 1 (Th1) versus type 2 
(Th2) response, SCCs from OTRs and from controls displayed a mixed Th1 and Th2 gene-
expression signature, while CD4 mRNA was diminished in OTRs.315 Interestingly, skin 
adjacent to SCC in OTRs showed a Th2 expression pattern compared to controls. These 
findings support the hypothesis that skin adjacent to SCCs in OTRs might contribute to a 
field effect associated with higher recurrence rates and more aggressive SCC behavior 
observed in OTRs.315  
Why plasma cell percentages were higher in SCCs from OTRs in our study is not easily 
explained; one possibility could be that this was due to higher B-cell percentages at the lateral 
margins in tumors from OTRs. Higher B-cell counts superficially in the dermis might be 
explained by increased recruitment from the upper vascular plexus, due to evolving/early 
SCCs in OTRs while tumors from controls were larger, probably older and therefore 
established lesions. Hence, higher B-cell percentages could imply higher transformation to 
plasma cells in OTRs, indicated by higher plasma cell percentages.  
Intriguingly, former studies of SCCs from OTRs have reported reduced cellular densities of 
peritumoral infiltrates75, 76, 228, 313, 314, a finding we could not confirm. However, assessment 
methods differed in all studies and none of the previous studies used a systematic and 
computer-supported counting approach.  
Lastly, 86% of the SCCs from OTRs and 50% of controls’ cases were from intermittently sun 
exposed anatomical sites in our study. The relevance of UVR induced immunosuppression in 
skin carcinogenesis, especially in OTRs, is not fully elucidated, but in the context of 
additional drug induced immunosuppression, it seems likely that immune function of 
inflammatory cells may be altered, while cellular densities stay unaffected.312  
 
Studies 2, 3, and 4: 
Population-based data showed elevated cancer risks in OTRs at a range of sites and the 
highest relative risk was noted for SCCs of the skin (120-fold increased). Risk of SCC varied 
dramatically according to type of the transplanted organ and increased with time, while risk 
of other (non-skin) cancers remained stable. These findings are in agreement with earlier 
reports and indicate that level of drug-induced immunosuppression and increasing age at 
transplantation are strong risk factors for SCC development.12, 27, 57, 60, 64, 254 An association to 
level of immunosuppression is probably also important for risk of BCC (6-fold increased), 
since risk estimates were significantly lower in liver OTRs, who need less 
immunosuppression compared to kidney and heart OTRs.6, 12, 316 The SCC to BCC ratio of 
approximately 1: 4 (1: 7 in Sweden) in the general population, has been claimed to be 
reversed in OTRs.6, 28, 29, 54, 61, 63 . In Study 4, the SCC to BCC ratio was far lower, 1: 1.7. This 
low ratio could reflect the short follow-up time used in this study. However, in a former 
Swedish study on skin cancer prevalence in groups of kidney OTRs with shorter and longer 
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time on immunosuppression a reversal of this ratio was not observed either; the SCC to BCC 
ratio was 1: 3 and 1: 2.52, 53  
Compared to HIV patients, in whom risk of SCC is only moderately increased (4-fold in a 
meta-analysis36), the risk of SCC is drastically higher in OTRs; this cannot be explained by 
the state of immunosuppression alone as the major contributor to SCC development. If that 
were the case, the risk should be much higher in HIV patients. This observation provides 
support for the presence of other factors contributing to SCC carcinogenesis in OTRs (such as 
immunosuppressive drugs) and argues for HPV infection being only a co-factor and not a 
major factor.26, 27, 36, 178  
According to time since transplantation, data from Studies 2 and 4 as well as from others61, 64, 
317 indicate, that BCCs develop already during the first few years after transplantation and 
that the BCC increase is almost linear. This is in contrast to SCCs, which develop slower 
initially and show a successive exponential increase with time after transplantation. In 
patients with multiple SCCs and multiple BCCs, almost exponential increases of cumulative 
incidences according to number of previous tumors were observed. Similar results have been 
obtained from studies at single centers.58, 61, 318, 319 Interestingly, OTRs who started with a 
SCC more often developed a subsequent SCC and OTRs who started with a BCC more 
frequently developed a subsequent BCC.61, 319 Furthermore, the risk of SCC was influenced 
by a subgroup of OTRs with many tumors developing at an accelerating rate with time since 
transplantation, indicating the strong need for identifying high-risk patient groups, in order to 
initiate skin cancer prevention measures early. 
The risk of BCC was considerably lower compared to SCC, indicating lower sensitivity to 
drug-induced immunosuppression and could be explained by the following arguments: BCC 
development is attributed to a different pattern of sun exposure compared to SCC, i.e. 
intermittent intense as opposed to chronic low intense; BCCs do not develop in multiple steps 
and there are no known precursor lesions, also supported by the activated Hedgehog pathway 
being the main tumor promoter in BCCs.84, 277 Also, as indicated by Study 1, immune 
surveillance seems of greater importance in SCCs. These factors in combination with the high 
proliferative rate in follicular epithelium and also in the basal cell layer of the epidermis, can 
explain the observed early BCC development after transplantation, and can also explain its 
high prevalence in fair-skinned populations of the industrialized world as a whole.  
The risk of melanoma when compared to risk of SCC and BCC was only moderately 
increased (2.2-fold), which is in agreement with other studies.27, 105, 106 In comparison with 
other immunosuppressive conditions, risk is similarly increased in HIV patients (2.6-fold), 
and also in patients with NHL (2.4-fold).36, 102 Similar risks in different conditions of 
immunosuppression indicate that melanoma development is probably not associated with a 
viral infection, and is probably less affected by drug-induced carcinogenesis, and that the 
residual immune surveillance seems to be adequate as long as other factors, e.g. genetic 
predisposition, type and number of melanocytic nevi as well as sun seeking behavior do not 
lead to imbalances.  
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In Study 3 few melanoma-related deaths occurred in thin melanomas, ≤1.0 millimeter pT1, 
however statistical analysis was not significant. However, Vajdic et al. have recently 
indicated worse survival of kidney OTRs with pT1 melanomas (HR 3.5)320, while a 
correlation to thickness was either not observed103 or only in thicker melanomas, i.e. >2.0 
millimeter, by others.106 The histological reassessment of melanomas from OTRs 
demonstrated a significantly higher Clark level compared to melanomas in the general 
population, while millimeter thickness was not significantly different. In melanoma, 
regression can sometimes be observed upon histological evaluation, with increased 
inflammatory reaction, vascularization, melanin phagocytosis, and fibrosis at the late stage, 
indicating an active host response.137 Only in two melanomas were abundant infiltrating 
lymphocytes (TILs) were observed, indicating that an intact host response is required for 
melanoma regression. Furthermore, a remnant of a melanocytic nevus adjacent to the 
melanomas was discovered in more than 70% of cases, the majority on the trunk. These 
variables, i.e. TILs and nevus, could not be statistically compared to data from the SMR, 
because they are not recorded. However, the proportion with a nevus in association to 
melanoma in OTRs was much greater in our study compared to what has been reported in 
melanomas from non-transplanted patients (approximately 20% – 30%).321-323 Whether this 
finding was due to chance is difficult to prove and would need comparison with matched 
cases from the general population, allowing also comparison of other clinical characteristics, 
for example clinical nevus status and skin phenotype. The high degree of nevus association 
indicates however, that in the context of immunosuppression some melanocytic nevi are able 
to acquire genomic instability172 and this might facilitate progression to melanoma, although 
the exact mechanisms are still unclear. All melanoma-specific deaths occurred within 5 years 
after diagnosis, which is in agreement with other studies106, 107, indicating that OTRs with 
melanoma, independent of tumor stage, should be examined more frequently for the first 5 
years, in order to detect early relapse.  
The risk of otherwise rare skin cancer types (KS and MCC) and of tumors located at mucosal 
skin-adjacent sites, as well as of lympho-proliferative diseases324 was also high in the cohort 
of Study 2. All these cancer types are associated with known oncogenic viral infections 
(HHV8, MCPyV, HPV and mainly Epstein-Barr virus); for example, risk of KS highly 
depends on viral prevalence in studied populations6, 143, 144, explaining why incidence is low 
in Swedish OTRs. The risk of these malignancies is considerably higher in HIV patients 
compared to OTRs, suggesting a greater residual immune function in OTRs, translating to a 
lesser risk of virus-associated malignancies in OTRs.26, 36, 178, 182 A number of other cancer 
types, for example renal cancer, multiple myeloma, melanoma, and leukemia, lack a 
confirmed viral etiology and are probably mainly associated with genetic mutations; these 
cancer types are increased in both HIV patients and OTRs.36 In the case of kidney cancer, risk 
is higher in kidney recipients compared to liver or heart and/or lung OTRs (Table 11), which 
is likely to be associated with the underlying condition of end-stage kidney disease.16 
Adnexal carcinomas were few in absolute numbers, but risk was increased in OTRs 
compared to the general population. Why the risk of adnexal skin cancers is increased is 
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however difficult to explain, due to the heterogeneity of this group. Different 
immunosuppressive drugs, such as AZA and CsA have been implicated for having effects on 
sebaceous and hair follicle derived tumor development. Additionally, undetected genetic 
predisposition (for example Muir Torre syndrome) can be a factor, and also HPV has been 
detected in adnexal skin tumors, however, data is too limited to be able to draw more certain 
conclusions.150, 151  
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7 CONCLUSIONS 
In SCCs from OTRs inflammatory cell infiltrates differed in the composition of cell types 
compared to controls, possibly indicating a more tumor-submissive microenvironment, 
speculatively towards type 2. Also, immune cell densities were similar, indicating a similar 
recruitment capacity in the tumor microenvironment of SCCs from OTRs. In consequence, 
altered functionality of immune cells in OTRs seems likely. These two conclusions can be 
summarized as the inflammatory paradox in SCCs from OTRs. 
The dramatic 120-fold increased risk of SCC in OTRs indicates that cumulative level of drug-
induced immunosuppression, also related to the type of transplanted organ, is the strongest 
risk factor for SCC development in OTRs. OTRs at highest risk of SCC development are 
those who already had one or more SCCs, and who are older at transplantation (60 years and 
above). 
The comparatively lower 6-fold risk of BCC in OTRs can be explained by the simpler 
genotype, which renders BCCs less sensitive to immune surveillance and also towards the 
direct carcinogenic effects of drugs. OTRs at highest risk of BCC development are those who 
had a SCC diagnosis before transplantation, and who are older at transplantation (65 years 
and above). 
Possible crucial factors for risk of melanoma-specific death in OTRs have been identified; 
these are a high association with a melanocytic nevus, a higher Clark level, and a reduction or 
absence of an inflammatory reaction to the established melanoma. These three factors, apart 
from established factors such as tumor thickness and pathological tumor stage, can have 
contributed to the observed 3-fold increased risk of death in OTRs. Therefore, larger studies 
including these variables are recommended. Furthermore, all nevi, especially on the trunk 
may be regarded as precursors of melanoma.  
Oncogenic viral infection drives cancer risk at certain anatomical sites, but the association of 
oncogenic virus infection to specifically SCC and BCC, and melanoma, in OTRs remains 
uncertain.  
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8 FUTURE PERSPECTIVES 
Posttransplantation malignancies, particularly the problem of skin cancer, will probably 
increase further during the coming decades. The number of available organs only restricts the 
number of transplantations while the demand is much greater. Organ transplantations are also 
increasing among children.19 When these individuals reach adulthood their risk of skin cancer 
may seriously influence their quality of life negatively. 
This group of patients and tumors can become the subject of comprehensive cross-
disciplinary molecular analyses with the objective of identifying tumor characteristics that 
could lead to a better understanding of skin carcinogenesis. However, very many tumors are 
needed for large-scale genome-wide analyses to reliably identify crucial, tumor-driving 
aberrations. In addition, the mode of influence of immunosuppressant medications on skin 
cancer development needs further investigation.  
The optimal scenario for future experimental studies is the prospective enrollment of groups 
of OTRs in surveillance trials, which include the regular collection of blood and tissue 
samples, possibly already pretransplantation. When tumors arise, direct sampling would be 
possible (frozen tissue), thereby facilitating genome wide analyses, including expression 
studies, for which fresh tumor material is the best choice. Such an approach would make 
comparison of different patient groups according to many different variables, for example 
according to organ type, age, gender, underlying disease, and drugs, possible. Also, the study 
of individuals who do not develop any malignancies posttransplantation can probably 
generate valuable insights into protective mechanisms. 
Transplant medicine faces imminent challenges to improve methods to manipulate immune 
cells in order to induce clinical and immunological long-term tolerance, with the aim of 
minimizing the current risk-spectrum and without exposing patients to new life-threatening 
risks. New immune modulating therapies rather than mainly immune suppressing drugs need 
to be developed in order to improve tolerance to the new organ and consequently lessen the 
risk of posttransplantation malignancies, hopefully with fewer side effects.  
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9 SVENSK SAMMANFATTNING 
Organtransplanterade patienter löper hög risk att utveckla olika typer av cancer efter 
transplantation. Risken är störst för hudcancer och varierar bland de olika typerna: 
Skivepitelcancer i huden (SCC), basalcellscancer (BCC) och malignt melanom i huden 
(melanom). De bakomliggande orsakerna är flera, men den långvariga dämpningen av 
immunsystemet (immunsuppression) är förmodligen viktigast. Immunsuppressionen är 
nödvändig för att motverka avstötning av det transplanterade organet, men leder samtidigt till 
försämrad ”tumorövervakning” och minskat försvar mot virusinfektioner.  
Det övergripande syftet med denna avhandling var att öka förståelsen för mekanismer som är 
involverade i den delvis kraftigt ökade risken för hudcancer hos organtransplanterade 
patienter. 
Målet för studie 1 var att få en bättre inblick i sambandet mellan SCC och det anslutande 
inflammatoriska cellinfiltratet. Andelen olika typer av inflammatoriska celler samt 
celltätheten (celler/mm2 tumörområde) i infiltratet räknades för jämförelse mellan 
transplanterade och icke transplanterade kontrollpatienter. Sammanfattningsvis skilde sig det 
inflammatoriska infiltratet vid SCC från organtransplanterade från kontrollernas med 
avseende på sammansättningen av celltyper, men inte i antal celler. Detta utfall var 
överraskande och kan innebära en mer ”tumörvänlig” miljö i anslutning till SCC hos 
transplanterade. 
För de övriga studierna användes sjukvårdsregister, exempelvis det svenska cancerregistret 
och det svenska melanomregistret, som båda är befolkningsbaserade: 
I studie 2 analyserades den övergripande relativa cancerrisken efter transplantation i den 
svenska gruppen av organtransplanterade från 1970 – 2008, vilken omfattade mer än 10,000 
patienter, i jämförelse med den allmänna befolkningen (SIR = standardiserad incidens ratio). 
Den relativa risken för cancer varierade med anatomiskt läge och med typ av transplanterat 
organ. Merparten av den ökade risken beror på en exceptionellt hög risk för SCC (120 gånger 
ökad). Risken var högst hos hjärt- och/eller lungtransplanterade (198 gånger ökad) och lägst 
efter transplantation av lever (32 gånger ökad). Under uppföljningen tredubblades risken för 
SCC över 20 år oavsett typ av transplanterat organ, medan risken för all cancer, exklusive 
SCC, förblev stabil. Riskökningen för SCC berodde främst på en undergrupp av patienter, 
som utvecklade nya tumörer i allt snabbare takt. Vidare påvisades tämligen hög relativ risk 
för sällsynta maligna hudtumörer som Kaposis sarkom, Merkelcellscarcinom och 
bihangstumörer liksom för tumörer i hudnära lokaler som munhåla, vagina, vulva, anus och 
penis. Slutligen påvisades kraftig förhöjd risk att utveckla en lung-, njur- och levercancer hos 
individer i de hjärt/lung-, njur- och levertransplanterade grupperna, vilken sannolikt har 
samband med underliggande sjukdomar och riskfaktorer snarare än immunsuppressionen.  
I studie 3 undersöktes kliniska och histologiska egenskaper hos 49 melanom och dödlighet i 
melanom hos transplanterade patienter i jämförelse med befolkningen. Melanomen hos de 
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organtransplanterade var mer avancerade vid diagnos med avseende på kliniskt stadium och 
Clarknivå, men däremot inte avseende millimeter-tjocklek. Risken att dö i melanom var 3 
gånger ökad hos de transplanterade jämfört med befolkningen, detta efter justering för ålder, 
kön, sjukvårdsområde och tidsperiod. Histologisk undersökning visade att 73% av alla 
melanom (36 av 49 fall) var associerade med en melanocytär nevus, ett födelsemärke, 
huvudsakligen av dysplastisk typ. Bålen var den vanligaste lokalen för nevusassocierat 
melanom (21/25, 84%). Fynden kan motivera ett förebyggande borttagande av nevi på bålen 
hos patientgruppen. Vidare uppvisade endast ett fåtal melanom ett anslutande kraftigt 
inflammatoriskt infiltrat. Vid melanom hos transplanterade kan möjligen även andra faktorer, 
förutom millimeter-tjocklek, påverka långtidsprognosen.  
I studie 4 undersöktes den relativa risken att utveckla basalcellscancer hos 4,023 individer, 
som transplanterades åren 2004 – 2011, i jämförelse med den svenska populationen (SIR), 
med hjälp av det 2004 etablerade basalcellscancerregistret. Relativ risk för BCC bland de 
transplanterade var 6 gånger ökad, högst hos njurtransplanterade (7 gånger) och lägst hos 
levertransplanterade (2.6 gånger). Risk för BCC ökade hos patientgruppen 65 år och äldre vid 
transplantation. I jämförelse med BCC, var SCC incidensen lägre och resulterade i en SCC 
mot BCC kvot av 1: 1.7; vilket var betydligt lägre än vad som tidigare rapporterats och kan 
ha samband med uppföljningstidens längd. 
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